AU4221393A - Constitutive and inducible epidermal vector systems - Google Patents
Constitutive and inducible epidermal vector systemsInfo
- Publication number
- AU4221393A AU4221393A AU42213/93A AU4221393A AU4221393A AU 4221393 A AU4221393 A AU 4221393A AU 42213/93 A AU42213/93 A AU 42213/93A AU 4221393 A AU4221393 A AU 4221393A AU 4221393 A AU4221393 A AU 4221393A
- Authority
- AU
- Australia
- Prior art keywords
- vector
- nucleic acid
- cassette
- acid sequence
- epidermal cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 title claims description 190
- 230000001939 inductive effect Effects 0.000 title claims description 54
- 150000007523 nucleic acids Chemical group 0.000 claims description 91
- 210000001339 epidermal cell Anatomy 0.000 claims description 89
- 108090000623 proteins and genes Proteins 0.000 claims description 67
- 108010076876 Keratins Proteins 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 62
- 102100031784 Loricrin Human genes 0.000 claims description 59
- 108010079309 loricrin Proteins 0.000 claims description 59
- 102000011782 Keratins Human genes 0.000 claims description 55
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 43
- 108020004707 nucleic acids Proteins 0.000 claims description 43
- 102000039446 nucleic acids Human genes 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 33
- 108020005065 3' Flanking Region Proteins 0.000 claims description 30
- 108020005029 5' Flanking Region Proteins 0.000 claims description 27
- 210000002615 epidermis Anatomy 0.000 claims description 25
- 238000001727 in vivo Methods 0.000 claims description 25
- 239000003102 growth factor Substances 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 238000010361 transduction Methods 0.000 claims description 20
- 230000026683 transduction Effects 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 17
- 108020005544 Antisense RNA Proteins 0.000 claims description 16
- 239000003184 complementary RNA Substances 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 14
- 101150100949 K6 gene Proteins 0.000 claims description 13
- 101150116870 LORICRIN gene Proteins 0.000 claims description 13
- 230000035876 healing Effects 0.000 claims description 13
- 108091008146 restriction endonucleases Proteins 0.000 claims description 12
- 108060003393 Granulin Proteins 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 208000002847 Surgical Wound Diseases 0.000 claims description 11
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 11
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 239000011710 vitamin D Substances 0.000 claims description 11
- 206010040943 Skin Ulcer Diseases 0.000 claims description 9
- 229930003316 Vitamin D Natural products 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- 206010052428 Wound Diseases 0.000 claims description 9
- 208000027418 Wounds and injury Diseases 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 231100000019 skin ulcer Toxicity 0.000 claims description 9
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 8
- 201000000849 skin cancer Diseases 0.000 claims description 8
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims description 7
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 7
- 210000004207 dermis Anatomy 0.000 claims description 7
- 230000002500 effect on skin Effects 0.000 claims description 7
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 6
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 6
- 108010085895 Laminin Proteins 0.000 claims description 6
- 108700026226 TATA Box Proteins 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 102000003675 cytokine receptors Human genes 0.000 claims description 6
- 108010057085 cytokine receptors Proteins 0.000 claims description 6
- 229940116977 epidermal growth factor Drugs 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 102100022987 Angiogenin Human genes 0.000 claims description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 108010072788 angiogenin Proteins 0.000 claims description 5
- 108010008217 nidogen Proteins 0.000 claims description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 238000002255 vaccination Methods 0.000 claims description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 108090000565 Capsid Proteins Proteins 0.000 claims description 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 3
- 102000004266 Collagen Type IV Human genes 0.000 claims description 3
- 108010042086 Collagen Type IV Proteins 0.000 claims description 3
- 102000004510 Collagen Type VII Human genes 0.000 claims description 3
- 108010017377 Collagen Type VII Proteins 0.000 claims description 3
- 101150071673 E6 gene Proteins 0.000 claims description 3
- 101150013359 E7 gene Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 239000003114 blood coagulation factor Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108010051696 Growth Hormone Proteins 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 2
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims description 2
- 108010076181 Proinsulin Proteins 0.000 claims description 2
- 102100038803 Somatotropin Human genes 0.000 claims description 2
- 102000028718 growth factor binding proteins Human genes 0.000 claims description 2
- 108091009353 growth factor binding proteins Proteins 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 108010076282 Factor IX Proteins 0.000 claims 2
- 102100023804 Coagulation factor VII Human genes 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 229940012413 factor vii Drugs 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 210000001082 somatic cell Anatomy 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 108700019146 Transgenes Proteins 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 8
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 7
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 239000011647 vitamin D3 Substances 0.000 description 7
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 102100026189 Beta-galactosidase Human genes 0.000 description 6
- 241000701806 Human papillomavirus Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108091029865 Exogenous DNA Proteins 0.000 description 4
- 102100023602 Protein Hook homolog 1 Human genes 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 108091023045 Untranslated Region Proteins 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003463 hyperproliferative effect Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108010077805 Bacterial Proteins Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 241000030538 Thecla Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108700025694 p53 Genes Proteins 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- YNJBLTDKTMKEET-ZLUOBGJFSA-N Cys-Ser-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O YNJBLTDKTMKEET-ZLUOBGJFSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LNLLNTMHVMIMOG-YUMQZZPRSA-N Gamma-glutamyl-Lysine Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CC[C@H](N)C(O)=O LNLLNTMHVMIMOG-YUMQZZPRSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000940873 Mus musculus Loricrin Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001307210 Pene Species 0.000 description 1
- IEIFEYBAYFSRBQ-IHRRRGAJSA-N Phe-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N IEIFEYBAYFSRBQ-IHRRRGAJSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000024622 response to vitamin Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Eye Examination Apparatus (AREA)
Description
>•»
5 -1-
CONSΉTU IYΈ AND INDUCIBLE EPIDERMAL VECTOR SYSTEMS
The invention was partially supported by a grant from the United States government under AR40240 awarded by the National Institutes of 10 Health. The government has certain rights in this invention.
¥WΛ,T> OF THE INVENTION
The present invention relates generally to expression vectors for use in expressing proteins and polypeptides in epidermal cells. More
15 particularly it relates to a constitutive vector consisting of the loricrin gene promoter, its 5' flanking region, its 5' transcribed but untranslated region, its intron, its 3' transcribed but untranslated region, its contiguous non-coding DNA containing the gene's natural transcriptional termination region and its 3' flanking region. It further relates to an
20 inducible vector consisting of the K6 keratin gene promoter, its 5' flanking region, its 5' transcribed but untranslated region, its first intron, its 3' transcribed but untranslated region, its contiguous non-coding DNA containing the gene's natural transcriptional termination region and its 3' flanking region. Additionally it relates to the treatment of disease
25 using the constitutive and inducible vectors.
BACKGROUND OF THE INVENTION
The skin is the largest organ in the human body and, due to its accessibility, it is an attractive target for gene therapy. The outer layer
30 of the skin is called the epidermis, and it is particularly attractive since epidermal cells can be grown in vitro from normal and affected patients,
are easily transformed genetically by vectors, and can be readily reintroduced by autografting. Previous studies investigating the feasibility of using epidermal cells for gene therapy have only considered this ex vivo approach. These investigations utilized retroviral vectors and their promoters to introduce and express foreign genetic material in epidermal cells. Even though the epidermis is avascular, these studies demonstrated that proteins expressed in the epidermis were able to traverse the epidermal-dermal barrier and achieve systemic distribution (Morgan et al., Science, Vol. 237, pp. 1476-1479, (1987)? Feiyves et al., PNAS USA, Vol. 86, pp. 8803-8807, (1989)fGarlick et al., J. Invest. Dermatol., Vol. 97, pp.
824-829, (1991)). The accessibility of the epidermis makes it suitable for other routes of vector delivery that do not require an ex vivo approach, e.g.. a gene gun (Sanford et al., Techniques, Vol. 3, pp. 3-16, (1991); Williams et al., PNAS USA, Vol. 88, pp. 2726-2730, (1991); Johnstone et al., In Vitro CeU Dev. Biol., Vol. 27, pp. 11-14, (1991)). In addition, novel vector systems derived from genes normally expressed at high levels in epidermal cells, could prove optimal for achieving efficient, as well as regulated, expression of exogenous DNA. These vector systems are the subject of this invention. The epidermis is a continuously regenerating stratified squamous epithelium. Differentiated epidermal cells are the progeny of proliferative cells located in the basal cell layer and there is substantial evidence suggesting that the regeneration process occurs in proliferative units composed of slowly cycling, self-renewing stem cells, proliferative but non- renewing transit amplifying cells, and post-mitotic maturing epidermal cells (Iversen, et al., Cell Tissue Kinet., Vol. 1, pp. 351-367, (1968); MacKenzie, et al., Nature, Vol. 226, pp. 653-655, (1970); Christophers, et al., J. Invest. Dermatol, Vol. 56, pp. 165-170, (1971); Potten, In Stem Cells: Their Identification and Characterization, pp. 200-232, (1983); Cotsarelis, et al., Cell, Vol. 61, pp. 1329-1337, (1990)). The maturation
process (terminal differentiation) is initiated when epidermal cells withdraw from the cell cycle and migrate from the basal layer into the spinous layer. Maturation continues as spinous cells migrate into the granular layer and terminates with the formation of the stratum corneum. Morphological and biochemical studies have shown that terminal differentiation occurs in stages. (Matoltsy, J. Invest. Dermatol., Vol. 65, pp. 127-142, (1975)). Keratins K5 and K14 are m τ products of basal epidermal cells (Woodcock-Mitchell, et al., J. Cell Biol., Vol. 95, pp. 580- 588, (1982)). These proteins assemble into 10 nm filaments (intermediate filaments [IF]) and, together with microtubules (tubulin) and microfilaments (actin), comprise the cytoskeleton of epidermal cells (Steinert, P.M., et al., Cell, Vol. 42, pp. 411-419, (1985)). One of the earliest changes associated with the commitment to differentiation and migration into the spinous layer is the induction of another differentiation-specific pair of keratins (Kl and K10). IF containing Kl and K10 replace those containing K5 and K14 as the major products of cells in the spinous layer (Woodcock-Mitchell, et al., J. Cell Biol., Vol. 95, pp. 580-588, (1982); Roop, et al., Proc. Natl. Acad. Sci., USA, Vol. 80, pp. 716-720, (1983); Schweizer, et al, Cell, Vol. 37, pp. 159-170, (1984)). The keratin IF formed by these proteins assemble into bundles. In the granular layer, another high molecular weight non-IF protein is synthesized, which is processed into filaggrin, and is thought to promote keratin filament aggregation and disulfide-bond formation (Dale, B.A., et al., Nature, Vol. 276, pp. 729-731, (1978); Harding, C.R., et al., J. Mol. Biol, Vol. 170, pp. 651-673, (1983)). In the final stage of epidermal cell maturation, transglutaminase catalyzes the crosslinking of involucrin and loricrin, by the formation of (γ-glutamyl) lysine isopeptides, into a highly insoluble comified envelope which is located just beneath the plasma membrane (Rice and Green, Cell, Vol. 11, pp. 417-422, (1977); Mehrel, et al., Cell, Vol. 61, pp. 1103-1112, (1990)).
Genes or cDNAs encoding the mqjor keratins expressed in epidermal cells have now been cloned: K5 (Lersch, et al., Mol. and Cell Biol., Vol. 8, pp. 486-493, (1988), K14 (Marchuk, et al., Proc. Natl. Acad. Sci, USA, Vol. 82, pp. 1609-1613, (1985); Knapp, et al., J. Biol. Chem, Vol. 262, pp. 938-945, (1987); Roop, et al., Cancer Res., Vol. 48, pp. 3245-3252,
(1988), Kl (Steinert, et al., J. Biol. Chem., Vol.260, pp. 7142-7149, (1985) and K10 (Krieg, et al., J. Biol. Chem., Vol. 260, pp. 5867-5870, (1985)). Northern blot analysis and in situ hybridization studies suggest that keratin genes K5 and K14 are predominantly transcribed in the proliferating basal layer and transcription of keratin genes Kl and K10 is induced as cells migrate into the spinous layer (Lersch, et al., Mol. and Cell Biol., Vol. 8, pp. 486-493, (1988); Knapp, et al., J. Biol. Chem, Vol. 262, pp. 938-945, (1987); Roop, et al., Cancer Res., Vol. 48, pp. 3245-3252, (1988)). Genes encoding rat (Haydock, et al., J. Biol. Chem., Vol.261, pp. 12520-12525, (1986)) and mouse (Rothnagel, et al., J. Biol. Chem., Vol.
262, pp. 15643-15648, (1987)) filaggrin have now been identified and in situ hybridization experiments have confirmed that transcription of this gene is restricted to the granular layer (Rothnagel, et al, J. Biol. Chem., Vol. 262, pp. 15643-15648, (1987); Fisher, et al. J. Invest. Dermatol, Vol. 88, pp. 661-664, (1987)). To date, loricrin is the only gene encoding a component of the comified envelope to be studied at the molecular level by in situ hybridization and transcripts of this gene are restricted to the granular layer (Mehrel, et al., Cell, Vol. 61, pp. 1103-1112, (1990)).
Since the genes encoding the structured proteins described above are expressed at very high levels, i.e. their individual transcripts represent
5-10% of the total messenger RNA in epidermal cells, their regulatory regions could be utilized in the construction of vectors to direct efficient expression of exogenous DNA in epidermal cells. In particular, efforts have focused on the gene encoding loricrin, a major keratinocyte cell envelope protein (Mehrel et al., Cell, Vol. 61, pp. 1103-1112, (1990)).
Although this gene is normally only expressed in the most differentiated layers of the epidermis, the present invention demonstrates that it possible to remove sequences that normally restrict expression of the loricrin gene in undifferentiated cells and achieve high levels of expression in undifferentiated epidermal cells (greater than the viral promoter of
SV40). Thus, this vector is constitutively expressed in epidermal cells at all differentiation states.
In addition to the constitutive vector, the present invention takes advantage of the expression characteristics of another gene encoding the K6 keratin to construct an inducible vector. The K6 gene is normally never expressed in the epidermis, but it can be induced under hyperproliferative conditions such as wound healing (Weiss, et al., J. Cell Biol, Vol. 98, pp. 1397-1406, (1984); Nakazawa, et al., J. Cell Biol, Vol. 103, pp. 561a, (1986); Stoler, et al., J. Cell Biol, Vol. 107, pp. 427-446, (1988) and topical application of retinoic acid (Rosenthal et al., J. Invest.
Dermatol, Vol. 95, pp. 510-515, (1990)).
SUMMARY QF THE INVENTIQN
An object of the present invention is a loricrin constitutive vector for efficient expression of nucleic acid sequences in epidermal cells.
An additional object of the present invention is a keratin K6 inducible vector for regulated expression of nucleic acid sequences in epidermal cells.
Another object of the present invention is an in vivo method of transducing epidermal cells with a constitutive or inducible vector.
A further object of the present invention is a bioreactor for producing proteins and polypeptides.
An additional object of the present invention is an enhanced method of wound healing or healing of surgical incisions.
Another object of the present invention is a method of treating skin ulcers.
An additional object of the present invention is a method of treating psoriasis. A further object of the present invention is a method of treating cancer.
Thus, in accomplishing the foregoing objects, there is provided in accordance with one aspect of the present invention, a loricrin constitutive vector for efficient expression of nucleic acid sequences in epidermal cells, comprising a 5' flanking region of the loricrin gene, said flanking region including a TATA box, a cap site and a first intron and an intron/exon boundary, all in appropriate sequential and positional relationship for expression of a nucleic acid cassette; a 3' flanking sequence of the loricrin gene; and a linker having a unique restriction endonuclease site at the location of the start and stop codon, said linker connecting the 5' flanking region to the 3' flanking sequence and said linker further providing a position for inserting the nucleic acid cassette which includes the specific nucleic acid sequence to be expressed.
In specific embodiments of the present invention, the loricrin constitutive vector has a 5' flanking region of approximately 1.5 kb, an intron of approximately 1.1 kb and a 3' flanking sequence of approximately 2.1 kb. In specific embodiments of the present invention, the loricrin constitutive vector also includes a poly-linker.
An alternative embodiment of the present invention is a keratin K6 inducible vector for regulated expression of a nucleic acid sequence in epidermal cells, comprising a 5' flanking region of the keratin K6 gene, said flanking region including a TATA box, a cap site, a first intron and an intron/exon boundary, all in sequential and positional relationship for expression of a nucleic acid cassette; a 3' flanking sequence of the keratin K6 gene; and a poly-linker having a pluraHty of restriction endonuclease
sites, said poly-linker connecting the 5' flanking region to the 3' flanking sequence and further providing a position for insertion of the nucleic acid cassette which includes the specific nucleic acid sequence to be expressed.
In specific embodiments of the present invention, the keratin K6 inducible vector, 5' flanking region of approximately 8.0 kb, an intron and intron/exon boundary of approximately 0.56 kb and the 3' flanking sequence of approximately 1.2 kb.
In the present invention, the restriction endonuclease sites in the linker or poly-linker are selected from the group consisting of Cla I, Not I, Xma I, Bgl II, Pac I, Xho I, Nhe I and Sfi I.
In one embodiment of the present invention, the nucleic acid cassette, of the constitutive or inducible vectors, contains a sequence coding for a protein, polypeptide or antisense RNA.
In specific embodiments of the present invention, there is a bioreactor comprising transduced epidermal cells including either the loricrin constitutive or keratin K6 inducible vectors. The bioreactor can produce a variety of compounds selected from proteins, polypeptides, antisense RNA.
In specific embodiments of the present invention, the loricrin constitutive or keratin K6 inducible vectors are used for the treatment of wounds, surgical incisions, psoriasis, skin ulcers and cancer.
The method of the present invention can also be used for vaccination by transducing epidermal cells with a loricrin constitutive or keratin K6 inducible vector having proteins or polypeptides which induce an immunological response.
Another embodiment of the present invention is the nucleotide sequences for the loricrin gene and loricrin constitutive vector.
Another embodiment of the present invention is the nucleotide sequences for the keratin K6 gene and keratin K6 inducible vector.
Other and further objects, features and advantages will be apparent from the following description of the presently preferred embodiments of invention which are given for the purposes of disclosure when taken in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a schematic drawing of the mouse loricrin gene and the constitutive epidermal vector derived from its regulatory sequences.
Figure 2 shows the expression characteristics of the constitutive epidermal vector in undifferentiated and differentiated epidermal cells utilizing a reporter gene encoding chloramphenicol acetyl transferase (CAT).
Figure 3 shows the expression characteristics of the constitutive epidermal vector in vivo utilizing a reporter gene encoding E. coli β-galactosidase.
Figure 4 demonstrates the suppression by Vitamin D3 of a novel negative regulatory element from the human Kl keratin gene (HK1.NRE).
Figure 5 is a schematic representative of the constitutive epidermal vector which can be suppressed by Vitamin Ds via insertion of the HK1.NRE.
Figure 6 is a schematic drawing of a derivative of the mouse K6 keratin gene (BCM-MK6(A)-HK1).
Figure 7 shows the expression characteristics of BCM-MK6(A)-HK1 in transgenic animals. Figure 8 is a schematic drawing of the mouse K6 keratin gene and the proposed construction of an inducible epidermal vector from its regulatory sequences.
Figure 9 is a schematic representative of the inducible epidermal vector which can be suppressed by Vitamin Ds via insertion of HK1.NRE.
The drawings are not necessarily to scale, and certain features of the invention may be exaggerated in scale and shown in schematic form in the interest of clarity and conciseness.
n yτAπ.F.n T F^RTPTTON O H . TNVF_NTTON
It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.
The term "transformed" as used herein refers to the process or mechanism of inducing changes in the characteristics (expressed phenotype) of a cell by the mechanism of gene transfer whereby DNA is introduced into a cell in a form where it expresses a specific gene product or alters expression of endogenous gene products.
The term "transduction" as used herein refers to the process of introducing a DNA expression vector into a cell. Various methods of transduction are possible, including microiηjection, CaPO<, lipofection (lysosome fusion), use of a gene gun and DNA vector transporter.
The loricrin constitutive vector and the keratin K6 inducible vector can be transduced into the squamous epithelia cells by any of the variety of ways described above. The types of epithelia cells include epidermis, oral, esophageal, vaginal, tracheal, coraeal and other squamous epithelia. They are transduced by contacting the vector with the cells. In the preferred embodiment this includes using a gene gun or DNA vector transporter. The term "DNA vector transporter" as used herein refers to those molecules which bind to DNA vectors and are capable of being taken up by epidermal cells. DNA transporter is a molecular complex capable of non-covalent binding to DNA and efficiently transporting the DNA through the cell membrane. Although not necessary, it is preferable that the transporter also transport the DNA through the nuclear membrane.
The term "nucleic acid cassette" as used herein refers to the genetic material of interest which can express a protein polypeptide or RNA and which is capable of being incorporated into the epidermal cells. The nucleic acid cassette is positionally and sequentially oriented within the keratin K6 inducible vector or the loricrin constitutive vector such that the nucleic acid in the cassette can be transcribed into RNA or antisense RNA and, when necessary, translated into proteins or polypeptides in the transformed epidermal cells. A variety of proteins and polypeptides can be expressed by the sequence in the nucleic acid cassette in the transformed epidermal cells. These proteins or polypeptides which can be expressed include hormones, growth factors, enzymes, clotting factors, apolipoproteins, receptors, drugs, tumor antigens, viral antigens, parasitic antigens and bacterial antigens. Specific examples of these compounds include proinsulin, insulin, growth hormone, insulin-like growth factor I, insulin-like growth factor II, insulin growth factor binding protein, epidermal growth factor TGF-α, dermal growth factor PDGF, angiogenesis factors, e.g., acid fibroblast growth factor, basic fibroblast growth factor and angiogenin for instance, matrix proteins such as Type IV collagen, Type VII collagen, laminin and proteins from viral, bacterial and parasitic organisms which can be used to induce immunologic response.
The genetic material which is incorporated into the epidermal cells using the loricrin constitutive vector or the keratin K6 inducible vector includes DNA not normally found in epidermal cells, DNA which is normally found in epidermal cells but not expressed at physiological significant levels, DNA normally found in epidermal cells and normally expressed at physiological desired levels, any other DNA which can be modified for expression in epidermal cells, and any combination of the above.
The term "loricrin constitutive vector" as used herein refers to a vector which can be inserted into epidermal cells and which once inserted,
will express a constitutive (i.e.- a constant level) of protein, polypeptide or antisense RNA from the nucleic acid cassette which is part of the loricrin constitutive vector. The loricrin constitutive vector is used for efficient expression of a nucleic acid sequence in epidermal cells and is comprised of a 5' flanking region of the loricrin gene, said flanking region including a TATA box, a cap site and a first intron and an intron/exon boundary all in appropriate sequential and positional relationship for expression of a nucleic acid cassette; a 3' flanking sequence of the loricrin gene; and a linker having a unique restriction endonuclease site at the location of the start and stop codon, said linker connecting the 5' flanking region to the
3' flanking sequence and said linker further providing a position for inserting the nucleic acid cassette.
The sequence for the loricrin gene which is used for preparing the loricrin constitutive vector is shown in SEQ. ID No. 1. The loricrin constitutive vector has a 5' flanking region comprising nucleotides 1 to
1540 of SEQ. ID. No. 1; an intron and intron/exon boundary comprising nucleotides 1587 to 2677 of SEQ. ID. No. 1, a 3' flanking region comprising nucleotides 4384 to 6530 of SEQ. ID. No. 1; and a linker to be inserted at the unique Cla I site at nucleotides 2700 to 2705 of SEQ. ID. No. 2. The loricrin constitutive vector has a 5' flanking region of approximately 1.5 kb, an intron of approximately 1.1 kb and a 3' flanking sequence of approximately 2.1 kb. The linker of the loricrin constitutive vector can be a poly-linker. The poly-linker includes a plurality of restriction endonuclease sites. The term "keratin K6 inducible vector" as used herein is a vector which is useful for regulated expression of a nucleic acid sequence in epidermal cells. The keratin K6 inducible vector comprises a 5' flanking region of the keratin K6 gene, said flanking region including a TATA box, a cap site, a first intron and an intron/exon boundary all in sequential and positional relationship for the expression of a nucleic acid cassette; a 3'
flanking sequence of a keratin K6 gene; and a poly-linker. The poly-linker includes a plurality of restriction endonuclease sites, connects the 5' flanking region to the 3' flanking sequence and further provides a position for insertion of the nucleic acid cassette. The partial sequence for the keratin K6 gene which is used for preparing the keratin K6 inducible vector is shown in schematic form in Figure 8 and the sequence is shown in SEQ. ID No. 3. The keratin inducible vector has a 5' flanking region which extends from a unique 5' Xho I site up to nucleotide 360 of SEQ. ID. No. 3; an intron and intron/exon boundary comprising nucleotides 928 to 1494 of SEQ. ID. No.
3; a 3' flanking region which- extends from nucleotide 4740 of SEQ. ID. No. 3 to a unique 3' Xho I site; and a poly linker inserted between nucleotides 1504 to 1509 of SEQ. ID. No. 3.
The keratin K6 inducible vector has a 5' flanking region of approximately 8.0 kb, an intron and intron/exon boundary of approximately 0.56 kb and a 3' flanking sequence of approximately 1.2 kb. The restriction endonuclease sites found in the linker and poly-linker of the loricrin and keratin K6 vectors can be any restriction endonucleases which will allow insertion of the nucleic acid cassette. In the preferred embodiment they are usually selected from the group consisting of Cla I,
Not I, Xma I, Bgl II, Pac I, Xho I Nhe I and Sfi I.
One skilled in the art will readily recognize that there are a variety of ways to introduce the loricrin constitutive vector or the keratin K6 inducible vector into epidermal cells. The vectors can be inserted either in vivo or ex vivo. The mode of insertion will, to a certain degree, determine the available methods for the insertion.
One embodiment of the present invention includes a bioreactor. A bioreactor is comprised of transformed epidermal cells which contain the loricrin constitutive vector or contain the keratin K6 inducible vector. Once the vector is inserted in the epidermal cells, the epidermal cells will
express the nucleic cassette and produce the protein, polypeptide or antisense RNA of interest. This can be done either in vivo or ex vivo. Any compound which can be encoded in, and expressed by, the nucleic acid cassette can be produced by the bioreactor. One method for ex vivo introduction of the loricrin constitutive vector or the keratin K6 inducible vector into epidermal cells includes a cotransfection of the vector with a selectable marker. The selectable marker is used to select those cells which have become transformed. The cells can then be used in any of the methods described in the present invention.
One specific embodiment of the present invention is a method for the enhanced healing of a wound or surgical incision. This method comprises the in vivo transduction of epidermal cells with a loricrin constitutive vector or a keratin K6 indu le vector. In either case, the nucleic acid cassette of said vector contains a nucleic acid sequence for a growth factor.
In the preferred embodiment for the treatment of wounds or surgical incisions, a plurality of vectors are introduced into the epidermal cells. In the plurality of vectors, the cassette of at least one vector contains a nucleic acid sequence for an epidermal growth factor (TGF-α), the cassette of at least one vector contains a dermal growth factor (PDGF), a cassette of at least one vector contains a nucleic acid sequence for a matrix protein to anchor the epidermis to the dermis, and a cassette of at least one vector contains a nucleic acid sequence for an angiogenesis factor. The sequence for matrix proteins can be selected from any sequences useful for the anchoring of the epidermis to the dermis but are usually selected from the group consisting of Type IV collagen, laminin, nidogen, and Type VII collagen. The angiogenesis factor is usually selected from the group consisting of acid fibroblast growth factor, basic fibroblast growth factor and angiogenin. The combination of the vectors
provides all of the necessaiy elements for quick and rapid enhancement of healing of wounds or surgical incisions. This procedure is very helpful in the case of plastic or reconstructive surgery. Furthermore, skin ulcers can be treated by following similar procedures as described for wound healing or surgical incision. These procedures are useful in animals and humans.
In the ex vivo approach for treating or healing wounds, surgical incisions and skin lesions, the vectors are first transduced into the epidermal cells ex vivo. The transformed epidermal cells are transplanted onto the animal or human to be treated.
Another embodiment of the present invention is a method for treating psoriasis. In this method, epidermal cells are transduced in vivo with a loricrin constitutive vector or a keratin K6 inducible vector. A nucleic acid cassette in said vector contains a nucleic acid sequence for a protein or polypeptide selected from the group consisting of TGF-β, a soluble form of cytokine receptor, and an antisense RNA. The cytokine receptor can be selected from the group consisting of IL-1, IL-6 and IL-8. The antisense RNA sequence is selected from the group consisting of TGF-α, IL-1, IL-6 and IL-8. In another embodiment of the present invention there is a method of treating cancer. This method comprises the steps of in vivo transduction of epidermal cells with a loricrin constitutive vector or a keratin K6 inducible vector into epidermal cells. The nucleic acid cassette of either vector contains the nucleic acid sequence coding for antisense RNA for the E6 or E7 gene of the human papilloma virus or coding for the normal p53 protein. Although the example given is for skin cancer, this same approach is used for cancers occurring in other squamous epithelial, since the constitutive and inducible vectors will also function in these tissue types.
It has been found that either the keratin K6 inducible vector or the loricrin constitutive vector can be further regulated by introducing the Vitamin D regulatory element into the vector. The Vitamin D regulatoiy element is usually introduced into the 3' flanking sequence. In the present invention, the Vitamin D regulatory element is from the human
Kl keratin gene. With the Vitamin D regulatory element in the vector, the expression of the nucleic acid cassettes can be suppressed by Vitamin D, a commonly used substance in animals and humans.
An additional embodiment of the present invention is a method for vaccination comprising the step of in vivo introduction of a loricrin constitutive vector into epidermal cells. The nucleic acid cassette in the vectors usually codes for a polypeptide which induces an immunological response. An example of this is the viral capsid protein from the human papilloma virus. One skilled in the art will readily recognize that any other variety of proteins can be used to generate a immunologic response and thus produce antibodies for vaccination.
The following examples are offered by way of illustration and are not intended to limit the invention in any manner.
EXAMPLE 1
MatiPB pf the Mouse Lprfcrin Gene
Although it is a major keratinocyte cell envelope protein, loricrin was not identified until 1990 (Mehrel, et al., Cell, Vol. 61, pp. 1103-1112, (1990)). The primary sequence of the loricrin protein was deduced from the overlapping cDNA clones described in Mehrel, id. To obtain the full gene, the cDNA clones were used to screen an EMBL-3 Balb/c mouse genomic library. The gene encoding loricrin was located within two Bam HI fragments of 3.4 and 3.1 kb. The coding sequence within this genomic fragment is identical to the cDNA sequences and is not interrupted by introns. There is, however, an intron in the 5' non-coding region that is
approximately 1.1 kb in length. In addition to the intron and coding sequence, there is approximately 1.5 kb of 5' flanking sequence and 2.1 kb of 3' flanking sequence.
EXAMPLE 2
Construction and characterization of a constitutive epidermal espreggjpft βctpr frpm the ropμse tøricrin gene
Although all of the regulatoiy elements of the loricrin gene have not been identified, a functional loricrin constitutive expression construct was designed as follows. Briefly, polymerase chain reaction (PCR) technology was used to delete the loricrin coding region, leaving the 5' and 3' flanking regions, 5' and 3' non-coding regions and the intron (Figure 1). A unique Cla I restriction site was engineered at the start (ATG) and stop (TAA) codons to allow easy insertion of exogenous gene cassettes. To assess the expression characteristics of this vector, a reporter gene, the bacterial gene encoding chloramphenicol acetyl transferase (CAT), was inserted into the Cla I site. The expression vector was analyzed by transient transfection into primary mouse epidermal cells. Positive (ρSV2.CAT, lane 1) and negative (pAlO.CAT, lane 2) control vectors were included in the assay (Figure 2). The loricrin expression vector had high activity in undifferentiated (low Ca" medium, lane 3) and differentiated (high Ca" medium, lane 4) epidermal cells, surpassing levels obtained with the strong promoter of the virus SV40. This result was unexpected, since previous in vivo studies had demonstrated that the loricrin gene was only expressed at a late stage of epidermal differentiation (Mehrel, et al., Cell, Vol. 61, pp. 1103-1112, (1990)), and indicates that additional flanking sequences are required to suppress loricrin expression in undifferentiated epidermal cells.
To analyze the expression characteristics of the loricrin vector in vivo, the bacterial gene encoding β-galactosidase was inserted into the Cla
I site. The β-galactosidase gene has frequently been used as a reporter gene to assess targeting specificity (MacGregor, et al., In: Methods in Molecular Biology, Vol. 7, pp. 217-235, (1991)). This construct was designated pML-β-gal and was used in the production of transgenic mice. This construct was digested with Apa I and subjected to preparative agarose gel electrophoresis to purify the pML-β-gal expression construct away from plasmid sequences (pGEM72) which might interfere with expression. The separated expression construct sequences were purified and recovered using NA 45 DEAE membrane (Schleicher & Schuell). DNA was precipitated and resuspended at 1-3 ng ul. ICR outbred female mice (Sasco) were given PMS and HCG to stimulate superovulation, mated to FVB males (Taconie) and resulting one-cell fertilized embryos were collected from the oviducts. DNA was micro-iηjected into the pronuclei and the embryos were surgically transferred to pseudopregnant recipient females (the result of mating ICR females with vasectomized BeD2F. males
(Taconie). Normal gestation and birth was allowed to continue and at approximately three weeks of age the pups were screened for evidence of the transgene using total genomic DNA extracted from the tail.
PCR analysis was performed on the extracted tail using oligo primers specific for β-galactosidase. Animals positive for the transgene were further analyzed to assess the expression characteristics of pML-β- gal. This was done by removing part of the ear and incubating the tissue in a staining solution containing X-gal. This was done by removing part of the ear and incubating the tissue in a staining solution containing X- gal. Typical results are seen in Figure 3 where a PCR positive animal expressed high levels of β-galactosidase in the epidermis (Figure 3b) while a PCR negative animal shows no such staining (Figure 3a) indicating that endogenous murine β-galactosidase is not expressed at sufficient levels in the epidermis to cause false positives in this assay. Intense X-gal staining
was detected in the basal compartment as well as the suprabasal, more differentiated layers.
To analyze the expression characteristics of the loricrin vector in vivo, the bacterial gene encoding β-galactosidase was inserted into the Cla I site. This data is shown in Figure 3. This observation indicates that the loricrin expression vector is useful as a constitutive vector to direct the efficient expression of exogenous DNA in both the undifferentiated and differentiated compartments of the epidermis.
EXAMPLE 3
Utilization of a novel Vitamin D. responsive element to modulate expression levels in the epidermis This example demonstrates that a novel negative regulatory element from the human Kl keratin gene (HKl.NRE) is able to suppress a heterologous promoter in response to Vitamin D3. The HKl.NRE is 70 nucleotides in length (see Figure 4). PCR technology was used to generate Bam HI and Bgl II sites at opposite ends of this fragment. This facilitates generating multiple copies of this fragment since ligation and digestion with Bam HI and Bgl II will select for oligomers which have ligated head to tail. Four tandem copies of the HKl.NRE were inserted into the Bgl II cloning site of pAlO.CAT. In the absence of Vitamin D3 this construct is highly expressed when transfected into primary mouse epidermal cells (Figure 4). The addition of increasing concentrations of Vitamin D3 to the culture medium completely suppresses transcription of this heterologous promoter. Thus, by using Vitamin D3, the activity of the expression vector is modulated. Figure 5 shows a schematic representative of a derivative of the loricrin constitutive epidermal vector which contains the HKl.NRE in its 3' flanking region. The activity of this vector within epidermal cells
can be suppressed by topical application of Vitamin D3, or an analogue, to the skin.
EXAMPLE 4 Isolation and characterization of a Mouse K6 Keratin Gene
Several laboratories have reported that keratin K6 is not expressed in normal epidermis, but is expressed under hyperproliferative conditions such as wounding (Weiss, et al., J. Cell Biol, Vol. 98, pp. 1397-1406, (1984); Nakazawa, et al., J. Cell Biol, Vol. 103, pp. 561a (1986); Stoler, et al., J. Cell Biol, Vol. 107, pp. 427-446, (1988)) or topical application of retinoic acid (Rosenthal, et al., J. Invest. Dermatol, Vol. 95, pp. 510-515, (1990). Although K6 expression does not occur in interfollicular epidermis, it does occur in hair follicles (Nakazawa, et al., J. Cell Biol, Vol. 103, pp. 561a, (1986)). Recent results indicate that there are two K6 cDNAs that differ in sequence in only a few nucleotides. These cDNA clones have been used to differentially screen a EMBL 3 Balb/c mouse genomic library and isolate two distinct K6 genes. These genes are closely linked within genomic DNA, i.e., arranged in tandem. They have almost identical 3' halves, including identical 3' non-coding and flanking regions. Interestingly, the 5' halves of the 2 genes differ greatly in their restriction fragment patterns. Sequence analysis of the region near the ATG shows many differences between the two genes. The sequence of one of these genes, designated BCM-MK6(A), is shown in SEQ. ID. No. 3. To determine the expression characteristics of this gene in vivo in transgenic mice, PCR technology was used to modify a 13.5 kb Xho I fragment containing BCM-MK6(A). Nucleotides encoding the C-terminal region of the K6 protein were deleted and nucleotides encoding the amino acid sequence SEQ. ID. No. 4 were inserted. These amino acids are at the C- terminal of human keratin Kl (Johnson, et al., PNAS, USA, Vol. 82, pp. 1896-1900, (1985)). A schematic representative of this derivative of the
ouse K6 gene (BCM-MK6(A)-HK1) is shown in Figure 6. Antisera have previously been generated against the HK1 C-terminal peptide (Rosenthal, et al., J. Invest. Dermatol, Vol. 95, pp.510-515, (1990)). These antibodies are monospecific for this human Kl peptide and allow expression of the derivatized BCM-MK6(A)-HK1 transgene to be followed against the expression pattern of the endogenous mouse K6 genes.
The derivatized mouse K6 transgene shown in Figure 6 was used in the production of transgenic mice as outlined in Example 2. Mice resulting from the initial iiyections were screened by PCR analysis for presence of the BCM-MK6(A)-HK1 transgene. Positive founders were initially analyzed for transgene expression as follows. A small ear biopsy was taken and after 48 hours a second biopsy was taken at the same site to score for expression during wound healing. Transgene expression was limited to hair follicles in the initial biopsy and was not present in interfollicular epidermis. Transgene expression was observed in the epidermis in the 48 hour biopsies, but only at the site of wounding. To further confirm the inducibility of the BCM-MK6(A)-HK1 transgene under hyperproliferative conditions, Fl generation offspring from the initial founders were treated topically with the hyperplasiogenic agent 12-0- tetradecanoylphorbol-13-acetate. Biopsies were taken before and 48 hours after topical application of this agent. Immunofluorescence was performed on frozen sections of these biopsies with antisera specific for the HK1 peptide. No expression was observed prior to the induction of hyperplasia, however, the BCM-MK6(A)-HK1 protein was expressed at very high levels in all layers of the epidermis 48 hours after hyperplasia was induced
(Figure 7).
EXAMPLE 5
Construction of an inducible epidermal expression vector from the mouse K6 pene (BCM-MK6(A)
Results obtained with the derivative of BCM-MK6(A) (Figure 7) indicate that all of the regulatory sequences required to suppress expression of this gene in normal epidermis and activate its expression under hyperproliferative conditions, such as in wounding healing or experimentally induced hyperplasia, are located within the 13.5 kb Xho I fragment (Figure 6). Therefore, an inducible vector was developed from this fragment. This vector is very useful in gene therapy applications where dosage of pharmaceuticals needs to be regulated. In addition, this vector is ideally suited for wound healing applications since it is induced during the wound healing process but suppressed after healing has occurred. Figure 8 illustrates how a vector is constructed from the BCM- MK6(A) gene. The vector is derived from the 13.5 kb Xho I fragment which contains the entire K6 gene. The same general strategy used in construction of the constitutive epidermal vector (Figure 1) is followed. The expression vector retains all of the 5' flanking sequences, the 5' non- coding sequences up to but not including the ATG, the first intron including the splice-sites of the intron-exon boundary and all of the 3' non-coding and flanking sequences after the TAA codon. A polylinker is engineered 3' of the first intron to allow easy insertion of exogenous DNA cassettes. These manipulations are performed through the use of PCR technology. Unique Xho I sites are conserved at the ends of the vector to allow easy amplification in pGEM vectors and excision for purification from plasmid sequences. Recent in vivo results indicate that the endogenous human K6 gene is inducible after topical appHcation of all- trans retinoic acid. Further, in vivo mouse experiments suggest that the vector shown in Figure 9 is inducible by topical appHcation of retinoic acid, or an analogue, to the skin.
EXAMPLE 6
Construction of a derivative of the inducible epidermal vector which could be suppressed bv Vitamin D. Even though the inducible epidermal vector depicted in Figure 8 is suppressed or silent in normal epidermis, it can be accidently induced as a result of ii-gury. Therefore, it is desirable to have an additional suppressor engineered into this construct. In addition, this suppressor is used to more tightly regulate pharmaceutical deHvery. This is achieved by insertion of the HKl.NRE described in Figure 4. Figure 9 shows a schematic representative of a derivative of the K6 inducible epidermal vector which contains the HKl.NRE in its 3' flanking region. The activity of this vector within epidermal cells is suppressed by topical appHcation of Vitamin D3, or an analogue, to the skin.
EXAMPLE 7
Utilization of the inducible epidermal vector in wound healing Greater than 3.5 milHon individuals develop skin ulcers. During normal healing, epidermal cells produce growth factors which affect not only epidermal cells but also cells within the dermis. In addition, epidermal cells synthesize several matrix proteins which provide an anchor to the underlying dermis. Many skin ulcers occur in patients with disorders such as circulatoiy problems and diabetes, and the normal healing process in impaired. The inducible epidermal vector is used to target the combined expression of growth factors, to accelerate growth of cells in both the epidermal and dermal compartments; matrix proteins, to increase tensile strength; and angiogenesis factors, to improve circulation, in an attempt to improve healing these patients.
EXAMPLE 8
Utilization of the constitutive epidermal vector in gene therapy apprpache? tp canςer
Skin cancer is by far the most common form of cancer with greater than 600,000 new cases reported each year. Several genes have been implicated in causing skin cancer, including loss or mutation of the host cell tumor suppressor gene, p 53 and expression of the E6 and E7 transforming genes of human papilloma virus (HPV). In vitro studies suggest that the normal or wild type p53 gene can revert the phenotype of maHgnant cells or induce programmed ceU death. The constitutive epidermal vector is used to target expression of the normal p53 gene to cause reversion to a non-maHgnant phenotype or induction of programmed death in vivo. In cancers where HPV is suspected of being the etiological agent, the constitutive vector is used to target expression of antisense RNA specific for the E6 and E7 genes of HPV.
EXAMPLE 9
Utilization of the epidermal vector systems in gene therapy apprpacheg tp pspriagis Psoriasis is a common inherited skin disease which affects approximately 4 milHon individuals in the U.S., 20 million world-wide. It is characterized by the presence of inflamed scaly skin. Although the specific defect for psoriasis is not known, inappropriate expression of growth factors, and cytokines appears to be responsible for its pathogenesis. Epidermal vectors are used to inhibit the mitogenic effects of positive growth factors produced in psoriatic lesions by expressing negative growth factors which induce growth arrest of epidermal cells.
The inflammation observed in psoriasis most likely results from inappropriate expression of cytokines. Targeted expression of soluble cytokine receptors prevents stimulation of an inflammatory infiltrate in
this disease. In another approach, antisense RNA is directed against transcripts of positive growth factors or cytokines. These approaches have therapeutic potential for other dermatoses resulting from inflammation. AU patents and pubHcations mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. AU patents and pubHcations which are incorporated herein by reference are incorporated to the same extent as if each individual pubHcation was specifically and individuaUy indicated to be incorporated by reference. One skiUed in the art wiU readUy appreciate that the present invention is weU adapted to carry out the objects and obtain the ends and advantages mentioned, as weU as those inherent therein. The bioreactors, nucleic acid sequences, transformed epidermal cells, loricrin constitutive vector and keratin K6 inducible vector, along with the methods, procedures, treatments, molecules of specific compounds described herein are presently representative of preferred embodiments, are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses wiU occur to those skiUed in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.
SEQUENCE LISTINO
(1) GENERAL INFORMATION:
(i) APPLICANT: Roop, Dennis R.
Rothnagel, Joseph A. Greenhalgh, David A.
(ii) TITLE OF INVENTION: CONSTITUTIVE AND INDUCIBLE EPIDERMAL VECTOR SYSTEMS
(iii) NUMBER OF SEQUENCES: 4
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Fulbright & Jaworski
(B) STREET: 1301 McKinney, Suite 5100
(C) CITY: Houston
(D) STATE: Texas (E) COUNTRY: U.S.A.
(F) ZIP: 77010-3095
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentin Release #1.0, Version #1.25
(vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Paul, Thomas D.
(B) REGISTRATION NUMBER: 32,714
(C) REFERENCE/DOCKET NUMBER: D-5405
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 713/651-5325
(B) TELEFAX: 713/651-5246
(C) TELEX: 762829
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6530 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:
GGATCCTGAT ATAGCTGTCT CTTTTGAGAC TATCCCGGGG CCTAGCAAAC ACAGAAGTGG 60
ATGCTCACAG TCAGGGATTG GGTGAATCACAGGGCCCCCA ATGTTGGAGC TAGAGAAAGA 120
ACCCAGGGAG CTGGGGGGAT CACCTGAGTT CATACTGTCC AAACTGAAAC AAGTGGCACA 180
AGTTTCTGAG AGCCAAAGTC TAATCAGGAT CGTTTAGATC ATTAATGCTC CCCCATAATT 240
AAGACAATTT CTGATTAGAA TTATTCTTTC AACACAGCTG GGTGGAACAA GGTTCAACAG 300
TGGTATCTTA ATAGCAACTG AGTTCCAATG ATGAAAGAAA GGAAAAACAC TATGTTCTTC 360
ATACACAGAG GGGGGCTGCT CTTGGCCCTA GGGTCATCAG AGAACTGAGT AAATCTTATA 420
GGAAAATAGT TAAGATGTCT TCACACACCT CCTTTCCAAT AGGGTTCAAG GGCAGGCATG 480
ATTGGAAGGA AAAGTGTTCT GTCATGTGAG AAAAGAGCAA AAGTATTAAT ATCACATACT 540
ATGTAGTACA TTCATATTTC ATAACTTCCA TTTTCATGTT TCTGTGAAAT AAATTATAGG 600
ATTCCTGCTT GGTAGACCAA ATGGGGATCA GACAGCTCAA CAATGAACAA GTACTCAGTA 660
ACTGCCCTGT TGGTGGCATT GCATGAACTA CTGTGCTTTG CCCATGGTGA CATAGCTTGA 720
AATAGTAATG GAAGACCTGA ACCCAACTGA GATCTCTAAG TACATTCCAC TCTATGGTGG 780
CATCTCAGAG GTCAGAGTCA CTGTGCAGCG CCATAGGACA TCAGAATCAA AGGGTCATGG 840
TGAAAAGGCT GCCAGGGTCT GTCTTGTTAG TTCTCACCTT TGTAAGTAAA GTCAGTAGTC 900
AGTAACAAAG ATCAAAACAC CTGCTCTCAC AAGGAATAAC TTAAAGTAGA CTAAAGTCAT 960
GCTAGTTACA GTGCTGTCTT TTCCGTGGTA CCATCCCAAA CTGGGAGCTG GGGACTCACG 1020
AACTCTCACA ACCAATAAAG TAAGCAGAAC AGAAGCAACC CAATGAAGTG TTCATGAAAC 1080
TGGAATGGAG AAATTGTGGC ATAAGAGATG GATTCTAAAλ TTTTGAGAAT TTCCAAGATA 1140
ATGAAATTAA AACCAAACAT CAAAATTGGA AAGATACAAC TGAACTAGCT TCTATGTCTT 1200
AGACAATGTC TTAGATCTCT AGATTCCGTA AGGCTGCTTC ACAAGTCTGC AACCTAGTCC 1260
TCTAGAATAG CCCTCTGGTT ATGGCACGCA ACCTATACAG AAGTTTTGAA AACAATTTCT 1320
GCCATCCACA CTGCTGGCCA TCTCTAATGA CCAACCTGCT CACTGTTACA TCAGAGAAGT 1380
GGCCAGTCAT ACACCAAACT GCCTATCCCT ATCCCAAGAA TTTGAAATCT TCATGAATGG 1440
GTCAATCCTT CCCCTGCAAT CACAGGGAGG AGGTGCCTGA TCAATAGATG AGTCAGAGCA 1500
GGACAAGAGT ATAAAACACA GGAGCACCAG TGTCCCTCAC ATCAGCATCA CCTCCTTCCC 1560
TCACTCATCT TCCCTGGTGC TTCAGGTAAG TGTGGGCTCT CCTGGCTGTC TGGTCTCTCC 1620
AGTTGGCCTT GCTCAGCTTG CAGAGAGGTT AAGGAACAGA GCCTTTCTCC CCTTTGGAAG 1680
GTACTCTGTT CAAATTGAGAAGGGCTTTAG GAAAGCACTG GGAGAGTGGT AAGCTGGTGC 1740
TGGGCAGATG ATGTGTCTGG TCTTCTGGGC AGAATGTTAAAACTTCACAA AGATATGACT 1800
ATCTCCTACT TCTCTGGCAC CCTGGGAGCT GAGGGTTAGA ATACTGGATG ACTGCAGTGG 1860
CAGGCCTCCA TGGGCTGGAT GAACCTTTTG AACCTGCCAG AAGTGGCTGA ATACACTATC 1920
AGGAAGGGAG AGGGACGATA AGTCATAGAA TGGTGCTGAT GGGAGATTTG AGAAGCCACA 1980
AAAACCCAAG CTCTGCTTTA TGAGGGCAGA TGTTCTGACA GATAAATGAC TTGTGAGGTG 2040
CTGAACTACA CAGCTTCCTA TTAGCTACAG CTAATTGGAG TCTACCAAAT TTAGACTCCT 2100
GCATATCTCA AAAAGATGTC TACTTTCTTC TGGTTAGATG TACTGGTCCAAAAGGTTCAG 2160
AGTTCTTCCA TTTGTTTGCA GACAGGACCA CAGTAGAGCT GTCTTGTCTAATAATTGGCC 2220
CTTGGAGGAT ATCTCACTCA ATAGGACAGA TCAAGAGTTT AAACTAAGGA CTTTATACAG 2280
GAAATGCTAA TGTCCAAACA AATCTTTTCT TATTGTGCTG GGAGTGGATA AAATCCACGT 2340
GGAATTTTTG CAACTTTCTA CTGAATTTAA AGAATCAGCA CTGGGACTTG GGAGCACCCT 2400
TAGACATGGA GTGTTTATTA ATGTAAGATCAAAAGCAGGT GGGAATGTGG GGGTTCTGCT 2460
TCCCAAATCA CATAGTAGAA GAAAGGCAGA GTTGAGGGAAAAGGGGGTCA CTATTAACGG 2520
GACTTTTGAA GAGCTAACCA GTCCAGGAAT GGAGTCCAGA CACCTAGTCT GCATAAAGCT 2580
AGGAGTCAGA AGTATGTTGG CATGGATGCA TCTGCCACCT TCACAGCGTC CTCTTGCTGC 2640
TGTTGGTCTA ATGTTGCTCT TCTGCTCTTC TTCCAGGGTT CCCCTTCTCC TTAAACAAGA 2700
TGTCTCACCA GAAAAAGCAG CCCACTCCCT GCCCTCCTGT GGGTTGTGGA AAGACCTCTG 2760
GTGGAGGAGG AGGCGGCGGC GGCTATTATA GCGGTGGCGG CTCTGGCTGC GGAGGCGGCT 2820
CATCTGGAGG AGGCTCTAGC TGTGGAGGCG GAGGCGGTGG TTCCTATGGAGGTGGTTCCA 2880
GCTGCGGCGG TGGAGGCGGC TCCGGTGGGG GCGTCAAGTA CTCCGGAGGC GGCGGTGGCT 2940
CTAGCTGCGG CGGCGGCTAC TCCGGAGGCG GTGGTGGCTC TAGCTGCGGC GGTGGCTACT 3000
CTGGGGGCGG CGGCGGCTCC AGCTGCGGAG GTGGCTACTC CGGAGGCGGC GGCGGCTCCA 3060
GCTGCGGCGG CGGCAGCTAC TCCGGGGGTG GCTCCAGCTG TGGAGGCGGT GGCGGCTCTG 3120
GTGGGGGCGT CAAGTACTCC GGAGGTGGTG GCGGCGGCGG CTCTAGCTGC GGCGGCGGCT 3180
CCTCCGGGGG CGGCGGCGGC GGCTCCAGCT GCGGAGGCGG ATCAGGAGGC GGCGGCTCCT 3240
ACTGCGGAGG CTCCTCTGGA GGCGGCAGCT CCGGTGGCTG CGGCGGCGGT TCCGGAGGCG 3300
GCAAGTACTC TGGTGGCGGC GGTGGCTCCA GCTGCGGAGG CGGCTATTCC GGCGGCGGTG 3360
GAAGCAGCGG CGGCTCTAGC TGTGGCGGCG GCTACTCAGG TGGCGGTGGA TCCAGCTGCG 3420
GCGGCGGCGG CGGCTATTCC GGTGGCGGCG GCACGAGCTG CGGAGGTGGT TCCTCCGGTG 3480
GCGGCGGCGG CGGATCGTCC CAACAGTATC AGTGCCAGAG CTACGGAGGC GGTTCTAGCG 3540
GTGGCTCCAG CTGCGGCGGC GGCTACTCCG GGGGCGGAGG CTCCAGCTGC GGTGGCGGCT 3600
ACTCCGGGGG CGGAGGCTCT AGCTGCGGAG GCGGCTCCTC TGGTGGTGGC TCCAGTTGCG 3660
GCGGCAGCGG CGGCGGCGGC TATTCCGGTG GTGGCGGTGG CAGCTGCGGC GGCGGCTCCT 3720
CTGGCGGCGG AGGGGGCTAT TACTCCTCTC AGCAGACCAG TCAGACCTCC TGCGCCCCCC 3780
AGCAGAGCTA CGGAGGGGGC TCTTCCGGAG GAGGTGGTAG CTGTGGAGGT GSCTCCTCTG 3840
GCGGCGGTGG CGGCGGTGGC TGCTACTCCA GCGGTGGTGG CGGCAGCAGC GGTGGCTGCG 3900
GTGGAGGCTA CTCCGGAGGC GGCGGTGGCT GTGGCGGCGG CTCTTCCGGG GGCAGCGGCG 3960
GTGGCTGCGG AGGTGGCTCT TCCGGAGGCA GCGGCGGTGG CTGCGGAGGA GGCTACTCCG 4020
GAGGCGGAGG CGGTGGCTCC AGCTGCGGAG GCGGCTCCTC TGGTGGCGGC TCTGGAGGTG 4080
GCAAGGGTGT GCCAGTCTGC CACCAGACCC AGCAGAAGCA GGCGCCTACC TGGCCGTGCA 4140
AGTAAGGTCA CCGGGTTGCA ACGGAGACAA CAGAGCTGGA AGAGTTCTCC GTGGGCGCCG 4200
ATGGGCTTAA CTTTCTCATG AATTTGCCTG AGGTTTCCAA ACCCTTCACA TTTTAAGCGC 4260
CCCTTCCCCCAGAAGAAGCC ATTGAGTCGC TCAAGGTGTA TCCTGTTCTG CAGATTTTTC 4320
ATCTTGGTTT CTGAATGACT ACCTCCCAAT TCTAGTGTCT CCTCAGTCAA TAAATTTGCT 4380
ATTCATGAGA ATCTCTGAGT TTGCTGTAGT CTTTGTAGCT TGCAAATTTA CTCAGTTCAT 4440
TCTGTGTTTG CTTTTTCCAT TCATTAGTTC ACATTTAAAT TCACTGAACA AGTGTTCTAT 4500
CCCAAGGTGG GGGAGTAGAT AGATGGAATG GGGCAAAGGA TGACCAAGGT TGTGAACAGT 4560
CTGGGGTGTGGCTTAAAAAT CATGAGATGG TCCTCAAACA CCAAGAAAAG TCTTCACTGG 4620
ACATCCTACA CATCACTGAA ATTGGGCCTG CGCAGGCAAT TTCTAGCAGT GCAGAGTTCA 4680
CTCTCCAAGT TCTGGAAGCA GGATGGCTCT CAGATTAGGT TAGCTACCAG AGGTCCAAGT 4740
CCACTGACAT GTTCTGACCT AAGAAGAAGGACATTCACCC CTGAACAAAA GACCCCTGCC 4800
CATGCGATCT TCCGGAACAC TATAACTACT TTCCTTACTC ATGACCCATGATAGAGCTTT 4860
GAGGCAAAGA TACAAACCCT CTATGTCTTC TCAAGATTGC CAGTTCTTCA TTAAGCCTGA 4920
TACCTTCTTA CCAGCGCACG TCTCCTGAAT ACTGATAAAG TCTGGTTTTG TTAGTCTGTT 4980
AGAAAAATAT TATATCAGAT AATCAAGATC CTCTACAGTG TGTGAGACAG TTTACTGAGC 5040
ATCTATAGAG ATAGAAGGCA GCCCTCTTGλ AGGATTGAAC GCGTACGTTT CGTCCAATTT 5100
GAGAAGGTAC ATCGTAAGTA TTTAAGATGC TTAACATCAG TATCACAGAG GTCACTGGAA 5160
ACATTAGGGG CCTCCTGATT AGCAAGCATA AAGCTAGAGT TGCTCAAAGG CATGTGTAAC 5220
AACCATCCCC TGGCCAGATC CTGTTTTACA GTCAGATTTT ATCAGCTTTA GGTAAATGCT 5280
AACTTACTGA CTTACTCAAG TTAATTTTGC TATACTAAAA AGCCAATGTG CCTTCCTACA 5340
TTTAGCTAAT GATAGAAATA AAAAGATTTC ATCTCACTCT TCCATTTGGA GTCATCACTA 5400
CCTTCATCAT TTGCATCAGA GATAGAGCAT GCCAAGTAGC AACCTCAGTG ACACAGTAGT 5460
CTTACCACCA CATTTTTATG GATTAAATGT ATTTTTTTTA GCATGGTTAT ATGTGCATAT 5520
AATACACTCT GATTACTCAC TTCCCTATCC TTTCTTACTC CTCCCCATCC CAACCTGTAT 5580
CAATCCTTAC CTTCCCTACA ATTCCCTTTA CCATGTTTTT GTTAGTTTTG TTGGTTTGTT 5640
TTGTGACCCA CTGAGCTAAC CAGGGCCATC TGTATGACCA TGGGTTTGGA TTCTGATGGA 5700
ATCCCACTGG GTACACAACT GAAACTAGTG ACTCCCCTTC ACAGAATCTA TCAGTAGACA 5760
ATAATTCAAC AGGGAATGGT GGGGCTCTCT CCATCCTTGG CTAACTGTTG ACAGGACAGT 5820
CTTGTGCAGG CCTAGTGCAG ACAACCATAG TTGCTGTGAG CTCATGTTTG CAATGGCTGT 5880
GTTATACATA GGAGATAGTA TTTTGGAGCC ATTATCCATG TCTGGCTCTT ATATTCCACC 5940
TTCTCTTTTA GGATGTTCCT TGAGTCTTTG AGGAATGTTT TGGTTAGAAC CGAGTGCTCA 6000
GTTGTCATTT ATTTTCAGAA TCTTGAGCAT CAAAGGATAC ATAAGATATT ATATTATAGG 6060
ATACTAAATT TTTGTACAGA TTTTTCATAT ACCCTTCATA TTGGTTAACC ATAATCCCCA 6120
ATTTTTCTCT CCTCTAACAC TCCACTGCTC CCATACCAGA TGAAACCTTT CAACTCCATG 6180
TATTTTCCCT CTTTGCTTTC ATTTTATCTA TATTGTATGA TCTCAACTCC CTTAATCTAT 6240
CTCACTACCA ATAACCCTTT TCTAAACTGG TAGCCTACAA CTTTAGTTCC AGTACTTGAT 6300
GCAGAAGTAG ATGGAGCAAT GTGAACTCAT GCTCAGCCTG GTCTATGGAA TGGGTTACAA 6360
GCCAGCCCGG ACTATGTAAT AGGACCCTGT CTCAAAAACA ACTAAACCAA ACAAACAAAC 6420
AAACAAAGAA CAAACAAACA AACAAACCAA AAATCTCAAC CATTTCTAGT TTTTCTAGTT 6480
TTTACTTGAA CATCAAGTTA AGCATAACTA AAGTTTCAAA AATAGGATCC 6530
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5092 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
GGATCCTGAT ATAGCTGTCT CTTTTGAGAC TATCCCGGGG CCTAGCAAAC ACAGAAGTGG 60
ATGCTCACAG TCAGGGATTG GGTGAATCAC AGGGCCCCCA ATGTTGGAGC TAGAGAAAGA 120
ACCCAGGGAG CTGGGGGGAT CACCTGAGTT CATACTGTCC AAACTGAAAC AAGTGGCACA 180
AGTTTCTGAG AGCCAAAGTC TAATCAGGAT CGTTTAGATC ATTAATGCTC CCCCATAATT 240
AAGACAATTT CTGATTAGAA TTATTCTTTC AACACAGCTG GGTGGAACAA GGTTCAACAG 300
TGGTATCTTA ATAGCAACTG AGTTCCAATG ATGAAAGAAA GGAAAAACAC TATGTTCTTC 360
ATACACAGAG GGGGGCTGCT CTTGGCCCTA GGGTCATCAG AGAACTGAGT AAATCTTATA 420
GGAAAATAGT TAAGATGTCT TCACACACCT CCTTTCCAAT AGGGTTCAAG GGCAGGCATG 480
ATTGGAAGGAAAAGTGTTCT GTCATGTGAG AAAAGAGCAA AAGTATTAAT ATCACATACT 540
ATGTAGTACA TTCATATTTC ATAACTTCCA TTTTCATGTT TCTGTGAAAT AAATTATAGG 600
ATTCCTGCTT GGTAGACCAA ATGGGGATCA GACAGCTCAA CAATGAACAA GTACTCAGTA 660
ACTGCCCTGT TGGTGGCATT GCATGAACTA CTGTGCTTTG CCCATGGTGA CATAGCTTGA 720
AATAGTAATG GAAGACCTGA ACCCAACTGA GATCTCTAAG TACATTCCAC TCTATGGTGG 780
CATCTCAGAG GTCAGAGTCA CTGTGCAGCG CCATAGGACA TCAGAATCAA AGGGTCATGG 840
TGAAAAGGCT GCCAGGGTCT GTCTTGTTAG TTCTCACCTT TGTAAGTAAA GTCAGTAGTC 900
AGTAACAAAG ATCAAAACAC CTGCTCTCAC AAGGAATAAC TTAAAGTAGA CTAAAGTCAT 960
GCTAGTTACA GTGCTGTCTT TTCCGTGGTA CCATCCCAAA CTGGGAGCTG GGGACTCACG 1020
AACTCTCACA ACCAATAAAG TAAGCAGAAC AGAAGCAACC CAATGAAGTG TTCATGAAAC 1080
TGGAATGGAG AAATTGTGGC ATAAGAGATG GATTCTAAAA TTTTGAGAAT TTCCAAGATA 1140
ATGAAATTAA AACCAAACAT CAAAATTGGA AAGATACAAC TGAACTAGCT TCTATGTCTT 1200
AGACAATGTC TTAGATCTCT AGATTCCGTA AGGCTGCTTC ACAAGTCTGC AACCTAGTCC 1260
TCTAGAATAG CCCTCTGGTT ATGGCACGCA ACCTATACAG AAGTTTTGAA AACAATTTCT 1320
GCCATCCACA CTGCTGGCCA TCTCTAATGA CCAACCTGCT CACTGTTACA TCAGAGAAGT 1380
GGCCAGTCAT ACACCAAACT GCCTATCCCT ATCCCAAGAA TTTGAAATCT TCATGAATGG 1440
GTCAATCCTT CCCCTGCAAT CACAGGGAGG AGGTGCCTGA TCAATAGATG AGTCAGAGCA 1500
GGACAAGAGT ATAAAACACA GGAGCACCAG TGTCCCTCAC ATCAGCATCA CCTCCTTCCC 1560
TCACTCATCT TCCCTGGTGC TTCAGGTAAG TGTGGGCTCT CCTGGCTGTC TGGTCTCTCC 1620
AGTTGGCCTT GCTCAGCTTG CAGAGAGGTT AAGGAACAGA GCCTTTCTCC CCTTTGGAAG 1680
GTACTCTGTT CAAATTGAGA AGGGCTTTAG GAAAGCACTG GGAGAGTGGT AAGCTGGTGC 1740
TGGGCAGATG ATGTGTCTGG TCTTCTGGGC AGAATGTTAA AACTTCACAA AGATATGACT 1800
ATCTCCTACT TCTCTGGCAC CCTGGGAGCT GAGGGTTAGA ATACTGGATG ACTGCAGTGG 1860
CAGGCCTCCA TGGGCTGGAT GAACCTTTTG AACCTGCCAG AAGTGGCTGA ATACACTATC 1920
AGGAAGGGAG AGGGACGATA AGTCATAGAATGGTGCTGAT GGGAGATTTG AGAAGCCACA 1980
AAAACCCAAG CTCTGCTTTA TGAGGGCAGA TGTTCTGACA GATAAATGAC TTGTGAGGTG 2040
CTGAACTACA CAGCTTCCTA TTAGCTACAG CTAATTGGAG TCTACCAAAT TTAGACTCCT 2100
GCATATCTCA AAAAGATGTC TACTTTCTTC TGGTTAGATG TACTGGTCCA AAAGGTTCAG 2160
AGTTCTTCCA TTTGTTTGCA GACAGGACCA CAGTAGAGCT GTCTTGTCTA ATAATTGGCC 2220
CTTGGAGGAT ATCTCACTCA ATAGGACAGA TCAAGAGTTT AAACTAAGGA CTTTATACAG 2280
GAAATGCTAA TGTCCAAACA AATCTTTTCT TATTGTGCTG GGAGTGGATA AAATCCACGT 2340
GGAATTTTTG CAACTTTCTA CTGAATTTAAAGAATCAGCA CTGGGACTTG GGAGCACCCT 2400
TAGACATGGA GTGTTTATTA ATGTAAGATCAAAAGCAGGT GGGAATGTGG GGGTTCTGCT 2460
TCCCAAATCA CATAGTAGAA GAAAGGCAGA GTTGAGGGAA AAGGGGGTCA CTATTAACGG 2520
GACTTTTGAA GAGCTAACCA GTCCAGGAAT GGAGTCCAGA CACCTAGTCT GCATAAAGCT 2580
AGGAGTCAGAAGTATGTTGG CATGGATGCA TCTGCCACCT TCACAGCGTC CTCTTGCTGC 2640
TGTTGGTCTA ATGTTGCTCT TCTGCTCTTC TTCCAGGGTT CCCCTTCTCC TTAAACAACA 2700
TCGATAAGGT CACCGGGTTG CAACGGAGAC AACAGAGCTG GAAGAGTTCT CCGTGGGCGC 2760
CGATGGGCTT AACTTTCTCA TGAATTTGCCTGAGGTTTCC AAACCCTTCA CATTTTAAGC 2820
GCCCCTTCCC CCAGAAGAAG CCATTGAGTC GCTCAAGGTG TATCCTGTTC TGCAGATTTT 2880
TCATCTTGGT TTCTGAATGA CTACCTCCCA ATTCTAGTGT CTCCTCAGTC AATAAATTTG 2940
CTATTCATGA GAATCTCTGA GTTTGCTGTA GTCTTTGTAG CTTGCAAATT TACTCAGTTC 3000
ATTCTGTGTT TGCTTTTTCC ATTCATTAGT TCACATTTAA ATTCACTGAA CAAGTGTTCT 3060
ATCCCAAGGT GGGGGAGTAG ATAGATGGAA TGGGGCAAAG GATGACCAAG GTTGTGAACA 3120
GTCTGGGGTG TGGCTTAAAA ATCATGAGAT GGTCCTCAAA CACCAAGAAA AGTCTTCACT 3180
GGACATCCTA CACATCACTG AAATTGGGCC TGCGCAGGCA ATTTCTAGCA GTGCAGAGTT 3240
CACTCTCCAA GTTCTGGAAG CAGGATGGCT CTCAGATTAG GTTAGCTACC AGAGGTCCAA 3300
GTCCACTGAC ATGTTCTGAC CTAAGAAGAA GGACATTCAC CCCTGAACAA AAGACCCCTG 3360
CCCATGCGAT CTTCCGGAAC ACTATAACTA CTTTCCTTAC TCATGACCCA TGATAGAGCT 3420
TTGAGGCAAA GATACAAACC CTCTATGTCT TCTCAAGATT GCCAGTTCTT CATTAAGCCT 3480
GATACCTTCT TACCAGCGCA CGTCTCCTGA ATACTGATAA AGTCTGGTTT TGTTAGTCTG 3540
TTAGAAAAAT ATTATATCAG ATAATCAAGA TCCTCTACAG TGTGTGAGAC AGTTTACTGA 3600
GCATCTATAG AGATAGAAGG CAGCCCTCTT GAAGGATTGA ACGCGTACGT TTCGTCCAAT 3660
TTGAGAAGGT ACATCGTAAG TATTTAAGAT GCTTAACATC AGTATCACAG AGGTCACTGG 3720
AAACATTAGG GGCCTCCTGA TTAGCAAGCA TAAAGCTAGA GTTGCTCAAA GGCATGTGTA 3780
ACAACCATCC CCTGGCCAGA TCCTGTTTTA CAGTCAGATT TTATCAGCTT TAGGTAAATG 3840
CTAACTTACT GACTTACTCA AGTTAATTTT GCTATACTAA AAAGCCAATG TGCCTTCCTA 3900
CATTTAGCTA ATGATAGAAA TAAAAAGATT TCATCTCACT CTTCCATTTG GAGTCATCAC 3960
TACCTTCATC ATTTGCATCA GAGATAGAGC ATGCCAAGTA GCAACCTCAG TGACACAGTA 4020
GTCTTACCAC CACATTTTTA TGGATTAAAT GTATTTTTTT TAGCATGGTT ATATGTGCAT 4080
ATAATACACT CTGATTACTC ACTTCCCTAT CCTTTCTTAC TCCTCCCCAT CCCAACCTGT 4140
ATCAATCCTT ACCTTCCCTA CAATTCCCTT TACCATGTTT TTGTTAGTTT TGTTGGTTTG 4200
TTTTGTGACC CACTGAGCTA ACCAGGGCCA TCTGTATGAC CATGGGTTTG GATTCTGATG 4260
GAATCCCACT GGGTACACAA CTGAAACTAG TGACTCCCCT TCACAGAATC TATCAGTAGA 4320
CAATAATTCA ACAGGGAATG GTGGGGCTCT CTCCATCCTT GGCTAACTGT TGACAGGACA 4380
GTCTTGTGCA GGCCTAGTGC AGACAACCAT AGTTGCTGTG AGCTCATGTT TGCAATGGCT 4440
GTGTTATACA TAGGAGATAG TATTTTGGAG CCATTATCCA TGTCTGGCTC TTATATTCCA 4500
CCTTCTCTTT TAGGATGTTC CTTGAGTCTT TGAGGAATGT TTTGGTTAGA ACCGAGTGCT 4560
CAGTTGTCAT TTATTTTCAG AATCTTGAGC ATCAAAGGAT ACATAAGATA TTATATTATA 4620
GGATACTAAA TTTTTGTACA GATTTTTCAT ATACCCTTCA TATTGGTTAA CCATAATCCC 4680
CAATTTTTCT CTCCTCTAAC ACTCCACTGCTCCCATACCA GATGAAACCT TTCAACTCCA 4740
TGTATTTTCC CTCTTTGCTT TCATTTTATC TATATTGTAT GATCTCAACT CCCTTAATCT 4800
ATCTCACTAC CAATAACCCT TTTCTAAACT GGTAGCCTAC AACTTTAGTT CCAGTACTTG 4860
ATGCAGAAGT AGATGGAGCA ATGTGAACTC ATGCTCAGCC TGGTCTATGG AATGGGTTAC 4920
AAGCCAGCCC GGACTATGTA ATAGGACCCT GTCTCAAAAA CAACTAAACC AAACAAACAA 4980
ACAAACAAAG AACAAACAAA CAAACAAACC AAAAATCTCA ACCATTTCTA GTTTTTCTAG 5040
TTTTTACTTG AACATCAAGT TAAGCATAAC TAAAGTTTCA AAAATAGGAT CC 5092
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5159 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
( i) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
GGGAAAACCT GTGTGGTGAG GGGGCACACA GGGAGTGTCT ACATGGGGCA AGAAGGAAAG 60
GGACAATTAT CACAGATCAG CTCCTTGTCT CTTTTGTTTG AGAAGATGAC TAACTCATGA 120
CTTAAGAGAA TTTACGTCCT GGCTCATTGT GTTCAGATCA AGTCAAGGCT GGAAGGCAGG 180
AGAATTTGCT CCGTGACTAA AGGAATCCAA AAGCAATCTT CATGTATCAT ACCTTTCTAG 240
AACTTGGGGG TGATCTCATT ATTTGTAAAG CCCTGCCCTA CCCACTCTGC AAGCTCACCA 300
TCAGGACCCA ACCCAGCCCA TCTGTACCAT ATATAAGCGG CTGCCCAGAG CTCAACACAC 360
TCATCTCTTC AGCTCTGCCC TGCCGTTTCT CTACTTCCCA GCCTTCTCAT CTCCAGGAAC 420
CATGTCTACC AAAACCACCA TCAAAAGTCA AACCAGCCAC CGTGGCTACA GTGCCAGCTC 480
AGCCAGAGTG CCTGGGCTCA ACCGCTCTGG CTTCAGCAGT GTGTCCGTGT GCCGCTCCCG 540
GGGCAGCGGT GGCTCCAGTG CAATGTGTGG AGGAGCTGGC TTTGGCAGCA GGAGCCTCTA 600
TGGTGTGGGG AGCTCCAAGA GGATCTCCAT CGGAGGGGGC AGCTGTGGCA TTGGAGGAGG 660
CTATGGCAGC CGATTTGGAG GAAGCTTCGG CATTGGAGGT GGAGCTGGTA GTGGCTTTGG 720
CTTCGGTGGT GGAGCTGGCT TTGGTGGTGG CTATGGGGGA GCTGGCTTCC CGGTGTGCCC 780
ACCTGGAGGC ATCCAAGAGG TCACCATCAA CCAGAGCCTC CTCACACCCC TGAACCTGCA 840
AATTGACCCC ACCATCCAGC GGGTCAGGAC TGAGGAGAGG GAGCAGATCA AGACCCTCAA 900
TAACAAGTTT GCCTCCTTCA TCGACAAGGT GAGACATGGT CCTCCCTAGA GCACCCTGTG 960
TGTCTACAGG GAATGCTGAA CAGAGGTGTA GGGAAGAGGC TTCAGTCTCA GCTCTGATAC 1020
TGCCTGTGTT GCTAGTTGAT GCTCTGTCCT GGTTTGTGTT CCTCTTCAGT TAGACTGGCA 1080
TCTGGAAATCAGGGTCAGCG TTCCTCTCCT CCAGAGGTTG CCCTATAAGG GTGTCTGGTC 1140
CCAGTGGACT GAGATGACTT AAAGACTCACAAAACAGGCT TGTAGGGAAA TGGAAGATTA 1200
TAACTATGTA TAGTGCAGTT GGGAGGCATG CCAGCCTCAC TAAGCTGCAG CACACTTCAT 1260
CAAGCCATGG CTAACCTGCC AGTGCCCTAC ATGAGTTCTC TGCCCTCCTT AGAGAGGTGG 1320
CATTGGGTGC TTCAGTCTGG ACTGTTTCCC TCAGACCCAG GGTCAGGGTC TAACTACACT 1380
GAATGAGTTT AGTCAGACAG CCTGAGAGGG TACACACACT AGTGAAGTGT TCATAGAAGG 1440
ATGAAACCCA AACTTCTCCC CCTCATACTT GCCCCCCCGC CCCCACCAGG TGCGGTTCCT 1500
GGAGCAGCAG AACAAGGTCC TGGACACCAA GTGGGCCCTG CTGCAAGAGC AGGGCACCAA 1560
GACCGTGAGG CAGAACCTGG AGCCTATGTT TGAGCAGTAC ATCAGCAACC TCCGCAGACA 1620
GCTGGACAGC ATCATTGGAGAGAGGGGTCG CCTGGACTCA GAGCTGAGGA ACATGCAGGA 1680
CACAGTGGAG GACTACAAGA GCAAGTGAGT TACAAAGAAG GGAGAATCCA GTCTCCGGAC 1740
TTTATAAAAA TGGAAGCCCA AATCTAAACA AGGGCTCCAT GATGTAAGAA AGCTTGGTCA 1800
CATCTGGGAC AGAGGCTGCC ATTGATACCA TCCACCCCGT GGCTCCAATA TAGTGCACCT 1860
TTCCTCTTGT AGATATGAAG ATGAAATCAA CAAGCGCACA GCAGCAGAGAATGAATTCGT 1920
GACCCTGAAG AAGGTGAGTT GACTAACCACAAGGATGGGT TTCTCTGCGG AATGACATAA 1980
AAGGCCTTGT ATATCTGCGT CATTCCAGAG AAATGGTGGT TACAGGGAAA GAAGTGAACG 2040
GTCTGGGGAA GAGAGGTAAC CTGATTCCAT GTTCTTGATG GTTTTCTCAG GATGTAGATG 2100
CTGCCTACAT GAACAAAGTT GAACTGCAAG CCAAGGCAGA CAGTCTAACA GATGATATCA 2160
ACTTCTTGAG AGCTCTCTAT GAAGCAGTAA GCCCCCCTTG TCTTCTCTTC TCCTTTCCAT 2220
TCACCACTCC CTTTATTTTT TTCCCCCTGG GCAAAGTGTT TGACCTCTGC AGTTCTCAAA 2280
GACAAAGATG ACTATGGCTC TTTCTGTCCT GCAGGAACTG TCTCAGATGC AAACTCACAT 2340
CTCAGACACA TCTGTGGTCC TCTCCATGGA CAACAACCGT AGCCTGGACC TGGACAGCAT 2400
CATCGCTGAG GTCAAGGCCC AGTATGAGGA CATTGCTCAG AGAAGTCGGG CTGAAGCTGA 2460
GTCCTGGTAC CAGACTAAAG TGAGTATTGG GGTGGAGGCT GATGGGGATG CCTGGGGTCC 2520
ACCCTGAACT CCATGAGTCT CTGAGTTCAG TATTGGAGGC CCACTAAAAG AAATAGGGAT 2580
GTTGTCCCAG AAAATGCACT GTGCACATGT ACCATAGAAT AATGTTTTAC TCGAAGAGTA 2640
AAAGAACACA GAGGTAGATG CAAAGTTGCC ATAAATGGGG TCCATGCTCT TTGCTTGAGC 2700
TGTACTCTGA ACAATGATCC TCTTGAGAAA CTAGAGAACA TTTTCACTTC CTGAGGGAAC 2760
TATGGAGTCT GTGGTCTCCT AAAGCTTCTC TTGAGGAAAA GCCAGCACAT CCATGGAAGT 2820
GTGTGCCACT CAGAGGTGGG TTTCGTTCCG CATGTAACAA CTCACATAGA TGTCCTCTCT 2880
TTGATTGGCC TTCAGTATGA GGAGCTGCAG GTCACAGCTG GCAGACATGG GGACGACCTG 2940
CGCAACACCA AGCAGGAGAT TGCTGAGATC AACCGCATGA TCCAGAGGCT GAGATCTGAG 3000
ATCGACCACG TTAAGAAGCA GGTGGGGTAG ACAGAGAAAT GCATGGGTTG CGGGTTGTGT 3060
TTCCTGTCCT CTAACTCTTG CTCACCAGAA ACCATGGTCT GGGGCTCAGC CTCTGCAGAG 3120
ATGTACACTC CACGATTATT TTTGTTGCTC TCTCTGCCCA GTGTGCCAAC CTGCAAGCTG 3180
CTATTGCTGA TGCTGAGCAA CGTGGGGAGA TGGCCCTGAA GGATGCCAGG GGCAAGCTGG 3240
AAGGGCTGGA GGATGCCCTG CAGAAGGCCA AACAGGACAT GGCCAGGCTG CTGAAGGAGT 3300
ACCAGGAACT CATGAATGTC AAGCTGGCCC TGGATGTGGA AATTGCCACC TACAGGAAGC 3360
TGCTGGAAGG AGAGGAGTGC AGGTGGGTAA CTATATCCTC CAACCCCTGA GGACAGCTCC 3420
TTGGTGCAAG CACTGAGCAC AAGAAGGGAG CACTGACTAT GCCCACAATA GTCCCTTTAA 3480
GAAACTCCTT GCTGTGCTGG AGAGATGGCT CATTGTTTAA GAGCACTAAC TCCTCTTCCA 3540
GAGTTACTGA GTTTAATTCC CAGCAACCAC CTGGTGATTC ACAATCATCT CTATTGAGAT 3600
CCAGTGCCCC CTTCTGGTGT GTTTGAAAAC AGCTACAGTG AACTAAAATACATATACTAA 3660
ATAAAGAATA TTTTTAAACA AACAAACAAA ACAAAACAAA CAAACAAACA ATCAACCCAA 3720
AACAAAACTC TAGTGGATTC TCTCTGAGCC TTCACTAGAT TGAGGCTTCCCATTCAGGCT 3780
GAAGTGATGG CTGCCTAGTT CTCACCTGTT GCTTTCCTCT TGTAGGTTGA ATGGTGAAGG 3840
TGTTGGACCA GTCAACATCT GTAAGTACTC TGCTTGTCCG AATCCCCTTC TCCTTACTTT 3900
GTGGCTTAAT TATCTGGTCA CAGTGGGCTGACCATGTCTG TGGTGTCCTT TTCCTCCTTC 3960
ACAGCTGTGG TGCAGTCCAC CGTGTCCAGC GGCTATGGCA GTGCCGGGGG TGCCAGCAGC 4020
AGCTTAGGCC TGGGTGGAGG CAGCAGCTAC TCCTATAGCA GCAGCCATGG CCTTGGAGGT 4080
GGCTTCAGTG CTGGCAGTGG CAGAGCCATC GGAGGTGGCC TCAGCTCTTC TGGTGGCCTC 4140
AGCTCTTCTA CCATCAAATA CACCACCACC TCCTCCAGCA AGAAGAGCTA CAGGCAGTGA 4200
ATTCTGTCAC CAAGAGCTTG TCTCTGGTCC CAGATGTCAT GGCTGCAGAA TCCTGTGCTC 4260
AGAGCCCCGA GTTCAGGGGC TTCTCCTCCC TGGACCCCAC CTCTGCTCCC TTCTTGGGAC 4320
TGAGGAGGCT GTGTCATTTT GCTCATATTT CTGTCCCCAT GGGTCCCCAC TGCTCATCTC 4380
TTTATAGTCA TCCTGTGAGC TTACATCACA ATTCACTCAC ATTTGGTGCT TCATGTTGTA 4440
TTTGGTTGCC AGGCTCCTGC CTCCCTACCT CTGTCTCTGA GGCTGCCTGT GACAGGGTGT 4500
TTCCGACACC TTCATTTTTG AAATCATTGT CTGGGTCCTA CTCAAGTAAT GAGCAGCTCC 4560
CTGTGAGTTT CTAATGGCCT GAGAAACCCC ATCTCTCAAC ATCATAACCC TCCCTGTCAG 4620 TAACTGTGAC TGCCCCGTCA CTGGTCCTGT GATGTAAGTT TCTGCTCATG TGATGTCTTT 4680
GCTTTCCTTG ATGCTCTTGG CTTCCTTGTA ATTTCTAAAT AAAGCAGGTT TATACATAAT 4740
AAAATTTTCC ACGTGCATTT TTTGTTGCAA TGTTTTTAAT ATAGAAATTC TGTGGCCTTG 4800
CTAGACAAGG CATCATTACA GTTCCCTCTC CCAGGTCTAT ATGTCTTCAT CTGTTAGTAT 4860
ATAGTTTAAA TTTAAGTTCA CATTTTAAAT TAATTTCAAT AACTTTTTAA ATAAAATAGA 4920
ATTCCATCAA TTCCCCCCCC TTCATTTTTC ACCTGCCCAG ATGTCTTCAC TCCAAACCCT 4980
CACCTGTTTC TCCATTTTCA AATTGAGAGT CTTTTGAGGA AGCCTATATT TCCTTCATTT 5040
TCTTATAAAT AATTTTGTAA TGTATCCATT TCCCTTTCTT TAAAGATAAT CAACAGATGT 5100
CAGTTCAGCG TTCCTTCCCA CATGAATTGC CTTCCTGTCA GCAAGAACAT GATCTGCAG 5159
(2) INFORMATION FOR SEQ ID NO: :
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Cys Ser Ser Val Lye Phe Val Ser Thr Thr Tyr Ser Gly Val Thr Arg 1 5 10 15
Claims (58)
1. A loricrin constitutive vector for efficient expression of a nucleic acid sequence in epidermal cells, comprising: a 5' flanking region of the loricrin gene, said flanking region including a TATA box, a cap site and a first intron and intron/exon boundary aU in appropriate sequential and positional relationship for expression of a nucleic acid cassette; a 3' flanking sequence of the loricrin gene; and a linker having a unique restriction endonuclease site at the location of the start and stop codon, said linker connecting the 5' flanking region to the 3' flanking sequence and said linker further providing a position for inserting the nucleic acid cassette.
2. The loricrin constitutive vector of claim 1, wherein the 5' flanking region is approximately 1.5 kb, the intron is approximately 1.1 kb and the 3' flanking sequence is approximately 2.1 kb.
3. The loricrin constitutive vector of claim 1, wherein the unique restriction site is selected from the group consisting of Cla I, Not I, Xma I and Bgl II, Pac I, Xho I, Nhe I and Sfi I.
4. The loricrin constitutive vector of claim 1, wherein the linker is a poly¬ linker, said poly-linker including a pluraHty of restriction endonuclease sites.
5. A keratin K6 inducible vector for regulated expression of a nucleic acid sequence in epidermal cells, comprising: a 5' flanking region of the keratin K6 gene, said flanking region including a TATA box, a cap site, a first intron and intron/exon boundary sequence all in sequential and positional relationship for expression of a nucleic acid cassette; a 3' flanking sequence of the keratin K6 gene; and a poly-linker having a pluraHty of restriction endonuclease sites, said poly-linker connecting the 5' flanking region to the 3' flanking sequence and further providing a position for insertion of the nucleic acid cassette.
6. The keratin K6 inducible vector of claim 5, wherein the 5' flanking region is approximately 8.0 kb and the intron and intron/exon boundary is approximately 0.56 kb and the 3' flanking sequence is approximately 1.2 kb.
7. The vector according to claims 1, 4 or 5, wherein the cassette includes a nucleic acid sequence coding for a protein or polypeptide selected from the group consisting of a hormone, a growth factor, an enzyme, a clotting factor, an apoHpoprotein, a receptor, a drug and a tumor antigen.
8. The vector according to claims 4 or 5, wherein the pluraHty of restriction endonuclease sites are selected from the group consisting of
Cla I, Not I, Xma I, Bgl II, Pac I, Xho I, Nhe I and Sfi I.
9. A method for in vivo transduction of epidermal cells with a loricrin constitutive vector comprising the step of contacting the vector with epidermal cells for sufficient time to transfect the epidermal cells.
10. A method for in vivo transduction of epidermal cells with a keratin K6 inducible vector comprising the step of contacting the vector with epidermal cells for sufficient time to transfect the epidermal cells.
11. A bioreactor comprising transformed epidermal cells including the loricrin constitutive vector of claim 1.
12. A bioreactor comprising transformed epidermal cells including the keratin K6 inducible vector of claim 5.
13. The bioreactor according to claims 11 or 12 wherein the loricrin constitutive vector includes a cassette having a nucleic acid sequence coding for a protein or polypeptide selected from the group consisting of a hormone, a growth factor, an enzyme, a drug, a tumor suppressor, a receptor, an apoHpoprotein, a clotting factor a tumor antigen, a viral antigen, a bacterial antigen and a parasitic antigen.
14. The bioreactor of claim 13, wherein the nucleic acid sequence encodes proinsulin or insulin.
15. The bioreactor of claim 13, wherein the nucleic acid sequence encodes growth hormone.
16. The bioreactor of claim 13, wherein the nucleic acid sequence encodes insulin-like growth factor I, insulin-like growth factor II or insuHn growth factor binding protein.
17. The bioreactor of claim 13, wherein the nucleic acid sequence encodes antihemophiHc factor (Factor VIII), Christmas factor (Factor IX) or
Factor VII.
18. The bioreactor of claim 13, wherein the nucleic acid sequence encodes an epidermal growth factor (TGF-α), a dermal growth factor (PDGF) or an angiogenesis factor.
19. The bioreactor of claim 13, wherein the nucleic acid sequence encodes Type IV coUagen, laminin, nidogen, or Type VII coUagen.
20. The bioreactor of claim 13 for vaccine production, wherein the cassette includes a protein which induces an immunological response.
21. A method for ex vivo introduction of a loricrin constitutive vector into epidermal cells comprising the steps of co-transfecting the vector with a selectable marker and selecting the transformed cells.
22. A method for ex vivo introduction of a keratin K6 inducible vector into epidermal cells comprising the steps of co-transfecting the vector with a selectable marker and selecting the transformed cells.
23. A loricrin gene of SEQ. ID. No. 1.
24. A loricrin constitutive vector having: a 5' flanking region comprising nucleotides 1 to 1540 of SEQ. ID. No. 1; an intron and intron/exonboundaiy comprising nucleotides 1587 to 1679 of SEQ. ID. No. 1; a 3' flanking region comprising nucleotides 4384 to 6530 of SEQ. ID. No. 1; and a linker to be inserted at the unique Cla I site at nucleotides
2700 to 2705 SEQ. ID. No. 2
25. A keratin K6 gene of SEQ. ID. No. 3.
26. A keratin K6 inducible vector having: a 5' flanking region which extends from a unique 5' Xho I site up to nucleotide 360 of SEQ. ID. No. 3; an intron and intron/exon boundary comprising nucleotides 928 to 1494 of SEQ. ID. No. 3. a 3' flanking region which extends from nucleotide 4740 of SEQ. ID. No. 3 to a unique 3' Xho I site; and a poly-linker inserted between nucleotides 1504 to 1509 of SEQ.
ID. No. 3
27. A method for enhanced healing of a wound or surgical incision comprising the steps of in vivo transduction of epidermal cells with a loricrin constitutive vector, wherein said vector includes a nucleic acid cassette having nucleic acid sequence for a growth factor.
28. A method of enhanced healing of a wound or surgical incision comprising the step of in vivo transduction of epidermal cells with a keratin K6 inducible vector, wherein said vector includes a nucleic acid cassette having a nucleic acid sequence for a growth factor.
29. The method according to claims 27 or 28, wherein the epidermal ceUs are transduced with a pluraHty of vectors and wherein the cassette of at least one vector includes the nucleic acid sequence of epidermal growth factor (TGF-α), the cassette of at least one vector includes dermal growth factor (PDGF), the cassette of at least one vector includes the nucleic acid sequence for a matrix protein to anchor the epidermis to the dermis and the cassette of at least one vector includes the nucleic acid sequence for an angiogenesis factor.
30. The method of claim 29, wherein the sequence for the matrix protein is selected from sequences coding for a protein selected from the group consisting of Type IV coUagen, laminin, nidogen and Type VII collagen.
31. The method of claim 29, wherein the angiogenesis factor is selected from the group consisting of acid fibroblast growth factor, basic fibroblast growth factor and angiogenin.
32. A method of treating skin ulcers comprising the steps of in vivo transduction of epidermal cells with a loricrin constitutive vector, wherein said vector includes a nucleic acid cassette having a nucleic acid sequence for a growth factor.
33. A method of treating skin ulcers comprising the steps of in vivo transduction of epidermal cells with a keratin K6 inducible vector, wherein said vectors include a nucleic acid cassette having a nucleic acid sequence for a growth factor.
34. The method according to claims 32 or 33, wherein the epidermal cells are transduced with a pluraHty of vectors and wherein the cassette of at least one vector includes the nucleic acid sequence of epidermal growth factor (TGF-α), the cassette of at least one vector includes dermal growth factor (PDGF), the cassette of at least one vector includes the nucleic acid sequence for a matrix protein to anchor the epidermis to the dermis and the cassette of at least one vector includes the nucleic acid sequence for an angiogenesis factor.
35. The method of claim 34, wherein the sequence for the matrix protein is selected from sequences coding for a protein selected from the group consisting of Type IV collagen, laminin, nidogen, and Type VII coUagen.
36. The method of claim 34, wherein the angiogenesis factor is selected from the group consisting of acid fibroblast growth factor, basic fibroblast growth factor and angiogenin.
37. A method of enhanced healing of a wound, surgical incision or skin ulcers in humans and animals comprising the steps of: ex vivo transduction of epidermal cells with a loricrin constitutive vector, wherein said vector includes a nucleic acid cassette a nucleic acid sequence for a growth factor; and transplanting said transduced epidermal cells into the animal or human to be treated.
38. A method of enhanced healing of a wound, surgical incision or skin ulcers in humans and animals, comprising the steps of: ex vivo transduction of epidermal cells with a keratin K6 inducible vector, wherein said vector includes a nucleic acid cassette having a nucleic acid sequence for a growth factor; and transplanting said transduced epidermal cells into the animal or human to be treated.
39. The method according to claims 37 or 38, wherein the epidermal cells are transduced with a pluraHty of vectors and wherein the cassette of at least one vector includes the nucleic acid sequence of epidermal growth factor (TGF-o), the cassette of at least one vector includes dermal growth factor (PDGF), the cassette of at least one vector includes the nucleic acid sequence for a matrix protein to anchor the epidermis to the dermis and the cassette of at least one vector includes the nucleic acid sequence for an angiogenesis factor.
40. The method of claim 39, wherein the sequence for the matrix protein is selected from sequences coding for a protein selected from the group consisting of Type IV coUagen, laminin, nidogen and Type VII coUagen.
41. The method of claim 39, wherein the angiogenesis factor is selected from the group consisting of acid fibroblast growth factor, basic fibroblast growth factor and angiogenin.
42. A method for treating psoriasis comprising the step of in vivo transduction of epidermal cells with a loricrin constitutive vector, wherein said vector includes a nucleic acid cassette having a nucleic acid sequence coding for a protein or polypeptide selected from the group consisting of TGF-β, a soluble form of cytokine receptor, and an antisense RNA.
43. A method for treating psoriasis comprising the step of in vivo transduction of epidermal cells with a keratin K6 inducible vector, wherein said vector includes a nucleic acid cassette having a nucleic acid sequence coding for a protein or polypeptide selected from the group consisting of TGF-β, a soluble form of cytokine receptor, and an antisense RNA.
44. The method of claims 42 or 43 wherein the cassette contains the sequence for TGF-β.
45. The method of claims 42 or 43 wherein the cassette contains a soluble form of cytokine receptor selected from the group consisting of IL-1, IL-6 and IL-8.
46. The method of claims 42 or 43 wherein the cassette contains antisense RNA to TGF-α, IL-1, IL-6 or IL-8.
47. A method of treating cancer of squamous epitheUa comprising the step of in vivo transduction of squamous epitheUa cells with a loricrin constitutive vector or a keratin K6 vector, said vector includes a nucleic acid cassette having a nucleic acid sequence coding for an antisense RNA.
48. The method of claim 47 wherein the squamous epitheUa cells are selected from the group of cells consisting of epidermis, oral, esophageal, vaginal, trachea! and coroeal epitheUa.
49. The method of claim 47 for treating skin cancer wherein transduction of epidermal cells is with a loricrin constitutive vector and said nucleic acid cassette has a nucleic acid sequence coding for an antisense RNA for the E6 or E7 gene of human papiUoma virus.
50. The method of claim 47 for treating skin cancer wherein transduction of epidermal cells is with a loricrin constitutive vector and said nucleic acid cassette has a nucleic acid sequence coding for the normal p53 protein.
51. The method of claim 47 for treating skin cancer wherein transduction of epidermal cells is with a keratin K6 vector and said nucleic acid cassette has a nucleic acid sequence coding for an antisense RNA for the E6 or E7 gene of human papiUoma virus.
52. The method of claim 47 for treating skin cancer wherein transduction of epidermal cells is with a keratin K6 vector and said nucleic acid cassette has a nucleic acid sequence coding for the normal p53 protein.
53. The vector according to claims 1, 4 or 5, further including a Vitamin D regulatoiy element.
54. The vector of claim 53, wherein the Vitamin D regulatory element is from the human Kl keratin gene.
55. A method for vaccination comprising the step of the in vivo transduction of epidermal cells with a loricrin constitutive vector or a keratin K6 inducible vector, wherein said vector includes a nucleic acid cassette having a nucleic acid sequence coding for a protein or polypeptide which induces an immunological response.
56. The method of claim 55, wherein the cassette includes a sequence for a viral capsid protein.
57. The method of claim 56, wherein the capsid protein is from the human papiUoma virus.
58. A transgenic animal containing the vector of claims 1, 4 or 5 in its germ and somatic cells, wherein said vector was introduced into said animal or an ancestor of said animal at an embryonic stage and the nucleic acid cassette of said vector is only expressed in squamous epitheUa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87628692A | 1992-04-30 | 1992-04-30 | |
| US876286 | 1992-04-30 | ||
| PCT/US1993/003993 WO1993022431A1 (en) | 1992-04-30 | 1993-04-28 | Constitutive and inducible epidermal vector systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4221393A true AU4221393A (en) | 1993-11-29 |
| AU669713B2 AU669713B2 (en) | 1996-06-20 |
Family
ID=25367356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU42213/93A Ceased AU669713B2 (en) | 1992-04-30 | 1993-04-28 | Constitutive and inducible epidermal vector systems |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0644933A4 (en) |
| JP (1) | JPH08501202A (en) |
| AU (1) | AU669713B2 (en) |
| CA (1) | CA2134670A1 (en) |
| WO (1) | WO1993022431A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2152753B1 (en) * | 1993-03-29 | 2001-09-01 | Ct Investig Energeticas Ciemat | TRANSGENIC ANIMALS FOR THE DETERMINATION OF AGENTS THAT STIMULATE OR REPRESSE EPIDERMIC HYPERPROLIFERATION AND HAIR GROWTH |
| AUPM746694A0 (en) * | 1994-08-15 | 1994-09-08 | Garvan Institute Of Medical Research | Expression vector |
| US6187993B1 (en) * | 1995-02-25 | 2001-02-13 | Imperial Cancer Research Technology Limited | Transgenic animals as model of psoriasis |
| US20030032610A1 (en) | 1996-06-03 | 2003-02-13 | Gilchrest Barbara A. | Method to inhibit cell growth using oligonucleotides |
| US5955059A (en) * | 1995-06-06 | 1999-09-21 | Trustees Of Boston University | Use of locally applied DNA fragments |
| US6147056A (en) * | 1995-06-06 | 2000-11-14 | Trustees Of Boston University | Use of locally applied DNA fragments |
| US7094766B1 (en) | 1995-06-06 | 2006-08-22 | Trustees Of Boston University | Use of locally applied DNA fragments |
| GB2324960A (en) * | 1997-05-09 | 1998-11-11 | Univ Manchester | Delivery of naked DNA for wound healing |
| AU2001251115A1 (en) | 2000-03-31 | 2001-10-15 | Trustees Of Boston University | Use of locally applied dna fragments |
| DK3079712T3 (en) | 2013-12-11 | 2022-04-25 | Massachusetts Gen Hospital | USE OF MÜLLER INHIBITANT SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863899A (en) * | 1983-05-09 | 1989-09-05 | Todaro George J | Biologically active polypeptides |
| ATE79138T1 (en) * | 1985-04-04 | 1992-08-15 | Univ Georgetown | TYPE-SPECIFIC PAPILLOMAVIRUS DNA SEQUENCES AND PEPTIDES. |
| US4806523A (en) * | 1985-08-06 | 1989-02-21 | Collagen Corporation | Method of treating inflammation |
| US4816464A (en) * | 1987-06-22 | 1989-03-28 | American Home Products Corporation | 10-Substituted benzo[b][1,6]naphthyridines as inhibitors of interleukin 1 |
| US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| JPH02109966A (en) * | 1988-10-20 | 1990-04-23 | Kirin Brewery Co Ltd | Radial flow packed bed bioreactor |
| US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
-
1993
- 1993-04-28 WO PCT/US1993/003993 patent/WO1993022431A1/en not_active Ceased
- 1993-04-28 EP EP93910875A patent/EP0644933A4/en not_active Withdrawn
- 1993-04-28 AU AU42213/93A patent/AU669713B2/en not_active Ceased
- 1993-04-28 JP JP5519487A patent/JPH08501202A/en active Pending
- 1993-04-28 CA CA002134670A patent/CA2134670A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08501202A (en) | 1996-02-13 |
| EP0644933A4 (en) | 1997-06-25 |
| WO1993022431A1 (en) | 1993-11-11 |
| AU669713B2 (en) | 1996-06-20 |
| EP0644933A1 (en) | 1995-03-29 |
| CA2134670A1 (en) | 1993-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kraner et al. | Silencing the type II sodium channel gene: a model for neural-specific gene regulation | |
| Kaddurah-Daouk et al. | Activation and repression of mammalian gene expression by the c-myc protein. | |
| Hayashi et al. | Lens-specific enhancer in the third intron regulates expression of the chicken delta 1-crystallin gene. | |
| JP3577323B2 (en) | Regulation of transcription and viral replication in mammalian cells by the tetracycline repressor | |
| Greene et al. | Multiple basal elements of a human hsp7o promoter function differently in human and rodent cell lines | |
| AU692196B2 (en) | Translational enhancer DNA | |
| DE69433461T2 (en) | Recombinant alphavirus vector | |
| AU749467B2 (en) | Compositions and methods for inducing gene expression | |
| CA2122617A1 (en) | Myogenic vector systems | |
| US6143727A (en) | Specific expression vectors and methods of use | |
| JPH11504502A (en) | Cells for production of recombinant adenovirus | |
| JP2001507203A (en) | Site-specific recombination method and vector therefor | |
| EP1214439A2 (en) | Smooth muscle cell promoter and uses thereof | |
| JPH10507061A (en) | Gene delivery vector and packaging cell line using plasmid DNA packaged in adenovirus | |
| US4599308A (en) | Protein from SV40 recombinants | |
| CN113874512A (en) | Compositions and methods for inducing hair cell differentiation | |
| WO1989002469A2 (en) | Human erythroid-specific transcriptional enhancer | |
| AU669713B2 (en) | Constitutive and inducible epidermal vector systems | |
| EP0652948B1 (en) | Development of a vector to target gene expression to the epidermis of transgenic animals | |
| JPH0235091A (en) | Control of manifestation in mammal cell | |
| CA2148492C (en) | Bovine heat shock promoter and uses thereof | |
| Ruether et al. | Cell-type-specific synthesis of murine immunoglobulin μ RNA from an adenovirus vector | |
| US20030219412A1 (en) | Somatic gene therapy to suppress secondary cataract formation following eye surgery | |
| Schaack et al. | Promoter strength in adenovirus transducing vectors: down-regulation of the adenovirus E1A promoter in 293 cells facilitates vector construction | |
| US20030109678A1 (en) | Methods and means for regulation of gene expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |